BUD Appendix

Sentara Healthcare
Pharmacy IV Sterile Compounding Beyond Use Dating Guidelines

Chart information reflects stability data based on manufacturer’s package insert or other clinical trials unless superseded by USP <797> Beyond Use
Dating Guidelines
Risk level Controlled room Controlled cold Controlled frozen Beyond Use Dating of Vials After Initial Opening
doi: 10.1310/hpj5108–654
temperature (RT) temperature (F) temperature
www.hospital-pharmacy.com
Multi-dose containers 28 days unless specified otherwise by
(20 to 25°C) (2 to 8°C) (-25 to -10°C) (MDV) manufacturer
Low 48 hours 14 days 45 days Single-dose containers (SDV) 6 hours within ISO class 5 environment,
Medium 30 hours 9 days 45 days unless specified otherwise by manufacturer
High 24 hours 3 days 45 days Single-dose ampules Storage not permitted
Legend
BUD: beyond use date hrs: hours LR: lactated Ringers PF: preservative free SubQ: subcutaneous
Conc: concentration IM: intramuscular MD: maintenance dose PI: package insert SWFI: sterile water for injection
D5W: dextrose 5% in water INH: inhalation NS: normal saline (0.9% PO: by mouth TB: tuberculin
sodium chloride)
EXP: expiration date (do not use after) LD: loading dose PBV: pharmacy bulk vial PVC: polyvinyl chloride TV: total volume (remove volume of drug
from diluent prior to admixing)
Vial specifics Secondary admixture specifics

Drug Vial size Diluent Reconsti- Reconstituted Infusion Dilution Finished Compounded Comments References
tuted or opened solution specifics product IV stability
vial concen- vial storage storage
tration
Abatacept F SWFI RT or F NS TV 100 mL RT or F 24 hrs EXP Follow PI PI BMS (2011)
(Orencia) 6 hrs (USP) instructions.
250 mg 10 mL 25 mg/mL ≤10 mg/mL Use provided
silicone-free syringe.
Do not shake.
Infuse over 30
minutes.
This supplementary material accompanies Hosp Pharm 2016;51(8):654–655 © 2016 Thomas Land Publishers, Inc.
Low-sorbing
infusion set
with inline filter
used during
administration.
(continued)
Drug Vial size Diluent Reconsti- Reconstituted Infusion Dilution Finished Compounded Comments References
tuted or opened solution specifics product IV stability
tration
Abciximab F 10 mg — 2 mg/mL Use NS TV 9 mg/ RT 12 hrs EXP Do not shake. PI Eli Lilly
(Reopro) immediately D5W TV 250 mL2 Use 0.22 or 5 µm (2005); 2
filter during prep.
Undiluted — Low-sorbing
infusion set
with inline filter
used during
administration.
Acetazolamide RT SWFI RT or F NS/D5W 50 or RT 24 hrs PI X-Gen
(Diamox) 6 hrs (USP) 100 mL (2014); PI
500 mg 5 mL 100 mg/mL Undiluted — F 3 days Lederle (1986)
500 mg 10 mL 50 mg/mL
Acetylcysteine RT 6 gm — 200 mg/mL Use D5W See RT 24 hrs LD = 150 mg/kg in PI Cumberland
(Acetadote) immediately 1/2NS comments 200 mL over 60 min Pharma (2013)
SWFI 2nd dose = 50 mg/
kg in 500 mL over
4 hrs
3rd dose = 100 mg/
kg in 1 L over 16
hrs
Acetylcysteine RT — — 100 mg/mL F Undiluted — RT See Sterile inhalation PI Hospira
(Mucomyst) — — 200 mg/mL 6 hrs (USP) comments syringe = RT 48 hrs (2004); 15
Non-sterile PO
syringe = RT 6
months15
Acyclovir RT SWFI RT NS ≤7 mg/mL RT 24 hrs PI GSK
(Zovirax) 500 mg 10 mL 50 mg/mL 6 hrs (USP) D5W (2003);
PI American
1 gm 20 mL 50 mg/mL (2004)
Solution - 50 mg/mL
(continued)
Drug Vial size Diluent Reconstituted Reconstituted Infusion Dilution Finished Compounded Comments References
vial concen- or opened solution specifics product IV stability
tration vial storage storage
Agalsidase beta F SWFI F NS TV F 24 hrs ** Read instructions PI Genzyme
(Fabrazyme) 6 hrs (USP) very carefully** (2010)
5 mg 1.1 mL 5 mg/mL ≤ 35 kg: 50 mL Allow vials to
reach room temp (~30
min)
35 mg 7.2 mL 5 mg/mL 35.1-70 kg: 100 mL Add water down
inside wall of vial.
70.1-100 250 mL Roll and tilt vial. Do
kg: not shake/agitate.
>100 kg: 500 mL Do not inject in the
airspace within bag.
Albumin (human) RT — — 0.05 g/mL RT Undiluted — RT 4 hours Use filter needle to 31; PI FFF
(5%) 4 hours withdraw Albutein (2011); PI
if administration set Baxter (2009);
— — 0.25 g/mL
not used. PI CSL (2007);
(25%)
PI Grifols
25% may 5 mg/mL31 If diluted, mix in
(2008)
be diluted in PVC-free bag.
D5W/NS
(continued)
Dehydrated alcohol RT — — 5 mL Use D5W 1000 mL RT Use immediately 100 mL dehydrated PI Akorn
98% immediately alcohol added to 900 mL (2011);
D5W produces a 10% PI American
solution.105 (2009); 105
Stability data lacking
Alglucosidase alfa F SWFI F NS TV 0.5-4 mg/mL F 24 hrs ** Read instructions PI Genzyme

(Lumizyme) 6 hrs (USP) very carefully** (2014)
50 mg 10.3 mL 5 mg/mL Protect from light.
20.1-30 kg: 150 mL Allow vials to reach
30.1-35 kg: 200 mL room temp (~30 min).
35.1-50 kg: 250 mL
50.1-60 kg: 300 mL Use 20 mL syringe to
60.1-100 kg: 500 mL draw up 10 mL then
100.1-120 kg: 600 mL add 0.3 mL to avoid
120.1-140 kg: 700 mL multiple entry to vial.
140.1-160 kg: 800 mL Use multi-ad injector
160.1-180 kg: 900 mL given by Genzyme.
180.1-200 kg: 1000 mL Slow drop-wise
addition of water
down inside of vial
not directly onto
powder.
Gently tilt and roll
vial; do not invert,
swirl, or shake.
Strands or fibers may
be observed in vials.
Remove air prior to
adding drug volume.
Gently invert or
massage the infusion
bag to mix. Do not
shake.
(continued)
Allopurinol RT SWFI RT NS ≤6 mg/mL RT 10 hrs from PI Bedford
(Aloprim) 500 mg 25 mL 20 mg/mL 6 hrs (USP) D5W reconstitution (2004)
Alpha-1 F — Provided See vial RT Provided — RT 3 hrs Do not shake. PI Talecris

proteinase 3 hrs Use provided transfer Biother-
(Prolastin) device/diluent/filter. apeutics
(2008)
Alprostadil (Prostin) F 500 mcg — 500 mcg/mL Use NS ≤20 mcg/mL F 24 hrs PI Upjohn
immediately D5W (1997)
Alteplase RT SWFI RT NS See comments RT See comments Conc 0.5-1 Do PI Genetech
(Activase, tPA) Provided 6 hrs (USP) D5W mg/mL: 8 hrs not (2005); 17; 18;
SWFI shake. 19; 94
Conc 0.0119,18 –
2 mg 2.2 mL 1 mg/mL 1 mg/mL94:
24 hrs (NS
only)
50 mg 50 mL 1 mg/mL INTRA-
PLEURAL: Use
100 mg 100 mL 1 mg/mL
immediately
Frozen See comments Frozen in
syringe:
45 days17
Thawed in
syringe: 8 hrs
Amifostine RT NS Use NS 5-40 mg/mL RT 5 hrs PI Ben Venue
(Ethyol) immediately (2009)
500 mg 9.7 mL (IV) 50 mg/mL F 24 hrs
500 mg 2.5 mL 200 mg/mL Undiluted —
(SubQ) (SubQ)
Amikacin RT — — 250 mg/mL RT NS 0.25-5 mg/mL F 14 days PI TEVA (2013)
(Amikin) 6 hrs (USP) D5W
(continued)
Aminocaproic RT 5 gm — 250 mg/mL RT NS TV 10-100 mg/ F 7 days20 PI Xanodyne
acid 6 hrs (USP) D5W TV mL20 (2001); 20
(Amicar)
Aminophylline RT — — 25 mg/mL RT NS ≤40 mg/mL21 RT 48 hrs21 Protect from light. PI Hospira
6 hrs (USP) D5W Aminophylline (2004); 21
25 mg = theophylline
19.7 mg
Amiodarone RT — — 50 mg/mL RT D5W TV 1-6 mg/mL2 RT 24 hrs2 Dispense in polyolefin PI Prism
(Cordarone) 6 hrs (USP) (non-PVC) container (2010);
if infusion exceeds 2 PI Wyeth
hours. (2005); 2
Solutions >2 mg/mL –
Central line only
Protect from light
during storage.
Amphotericin B F SWFI F D5W IVPB conc.2 F 14 days Verify product name. PI Xgen
conventional 50 mg 10 mL 5 mg/mL 6 hrs (USP) ≤0.1 mg/mL (0.1-0.25 mg/ Protect from light. (2010) 22; 2
(Fungizone) (peripheral) mL)22
≤ 0.25 mg/mL 2 days

(central) (≤0.1 mg/mL)2
SWFI 5 mg/mL F 7 days2 Protect from light.
(inhalation)
Amphotericin B F SWFI F D5W 1-2 mg/mL F 6 hrs Verify product name. PI Astellas
liposome 50 mg 12 mL 4 mg/mL 6 hrs (USP) Use 5 micron filter in (2012)
(Ambisome) box; one filter/vial.
Incompatible with
saline.
(continued)
Amphotericin B F 100 mg — 5 mg/mL Use D5W 1 mg/mL F 48 hrs Verify product name. PI Liposome
lipid complex immediately Shake well. Company
(Abelcet) (1999)
Use 5 micron filter in
box; one filter needle
for up to 4 vials
Incompatible with
saline.
Ampicillin RT SWFI RT NS ≤30 mg/mL F 48 hrs Also compatible in PI Sandoz
1 gm 7.4 mL 125 mg/mL 1 hr (≤ 20 mg/mL) D5W and other fluids, (2009);
but affects stability PI Pfizer
2 gm 14.8 mL 125 mg/mL 24 hrs (2010)
(21-30 mg/
mL)
RT 8 hrs
Ampicillin- RT SWFI F NS ≤45mg/mL F 72 hrs (≥31 PI Pfizer
subactam 1.5 gm 3.2mL 375 mg/mL 1 hr mg/mL) (2007)
(Unasyn)
*Combined 3 gm 6.4mL 375 mg/mL 48 hrs
components* (≤ 30 mg/mL)
RT 8 hrs
Anidulafungin F SWFI RT NS/D5W 50 mg/65 mL RT 48 hrs PI Roerig
(Eraxis) 50 mg 15 mL 3.33 mg/mL 6 hrs (USP) 100 mg/ (2012)
130 mL
100 mg 30 mL 3.33 mg/mL 200 mg/
260 mL
Antiehemophilic F — Provided — 3 hrs Undiluted — RT 3 hrs Following PI PI Baxter
factor VIII instructions (2011)
(Advate)
Anti-thymocyte F 250 mg — 50 mg/mL Use NS ≤4 mg/mL F 24 hrs EXP Do not mix in D5W PI Pharmacia
globulin (equine) immediately D5-1/2NS alone. & Upjohn
(Atgam) D5-1/4NS (2013)
Anti-thymocyte F SWFI Use NS 25 mg/50 mL F 24 hrs EXP Do not shake. PI Genzyme
globulin (rabbit) 25 mg 5 mL 5 mg/mL immediately D5W (2008)
(Thymoglobulin)
(continued)
Argatroban RT 250 mg — 100 mg/mL RT or F NS/D5W 1 mg/mL RT 48 hrs Protect from light. PI GSK (2009)
6 hrs (USP) LR F 96 hrs
Ascorbic acid F 25 gm — 500 mg/mL F NS Stability RT 24 hrs32 Protect from light.32 PI Mylan
4 hrs2 D5W concentration (2012); 1; 2;
= 10 mg/mL32 32
Atracurium F 50 mg — 10 mg/mL F RT NS 0.2-5 mg/ RT or F 24 hrs4,95 Unopened vials have PI Sagent
(Tracrium) 100 mg 14 d 6 hrs D5W mL4,95 RT BUD of 14 days. (2011); 4; 95
MDV SDV
Azithromycin RT SWFI RT NS 1-2 mg/mL F 7 days2 PI Baxter
(Zithromax) 500 mg 4.8 mL 100 mg/mL 6 hrs (USP) D5W RT 24 hrs (2007); 2
Aztreonam RT SWFI RT or F NS NS F 7 days Defrosting frozen PI BMS

(Azactam) 1 gm 5 mL 200 mg/mL 6 hrs (USP) D5W manufacturer product: (2007)
Defrosted at RT = 48
2 gm 10 mL 200 mg/mL D5W hrs
≤20 mg/mL Defrosted in refrig =
D5W RT Use 14 days
>20 mg/mL immediately
Bacitracin NS F NS Not specified F 7 days For irrigation only PI Novaplus
50,000 9.8 mL 5,000 units/ 6 hrs (USP) (2012)
units mL
Banana bag See individual components NS — F or RT 24 hrs Protect from light. 16

(MVI, folic acid, thiamine, pyridoxine, ascorbic D5W
acid, etc.)
Basiliximab F SWFI RT – 4 hrs NS 0.4 mg/mL F 24 hrs Do not shake. PI Novartis
(Simulect) 10 mg 2.5 mL 4 mg/mL F – 6 hrs (USP) D5W (2005)
20 mg 5 mL 4 mg/mL
(continued)
Belatacept F SWFI Use NS TV 2-10 mg/mL F 24 hrs EXP *** Follow PI PI BMS
(Nulojix) immediately D5W TV instructions*** (2011)
250 mg 10.5 mL 25 mg/mL Use silicon-free
syringe included
in the package for
reconstitution &
transfer.
Attach/send with
low-sorbing infusion
line w/ low-protein
binding filter.
Protect from light.
Do not shake.
Belimumab F SWFI F NS TV 250 mL F or RT 8 hrs EXP Allow vial to stand PI Human
(Benlysta) 120 mg 1.5 mL 2 80 mg/mL 6 hrs (USP) from time of 10-15 min to reach Genome
reconstitution room temp. (2011); 2
400 mg 4.8 mL2 80 mg/mL Reconstitution may
take up to 15-30 min.
Inject toward side of
vial.
Do not shake.
Protect from light.
Betamethasone RT 30 mg — 6 mg/mL RT Undiluted — RT 30 hrs Protect from light. PI Merck
(Celestone 28 days (2012)
Soluspan)
Bevacizumab F 100 mg — 25 mg/mL F NS TV 100 mL F 48 hrs PI Genentech
(Avastin) 400 mg — 25 mg/mL 6 hrs Undiluted — F 9 days 23
Use 5-micron filter. (2013);
(intravitreal) PI Roche
(2013); 23
(continued)
Bivalrudin RT SWFI F D5W 125 mg/250 RT 24 hrs PI Medicines
(Angiomax) 250 mg 5mL 50 mg/mL 6 hrs (USP) NS mL (0.5-5 mg/mL) (2010)
Botulinum A NS F Undiluted — F 24 hrs PI Allergan

(Botox) 100 4 mL 2.5 6 hrs (USP) (2011)
units units/0.1
mL
Bumetanide RT — — 0.25 mg/mL RT Undiluted — RT 30 hrs Protect from light. PI Roche
(Bumex) 6 hrs – SDV (2004)
28 days –
MDV
C1 esterase F SWFI RT Undiluted — RT 8 hrs Refer to PI for prep PI CSL
inhibitor human provided 6 hrs (USP) from time of instructions. Behring
(Berinert) reconstitution Must use provided (2009)
500 mg 10 mL 50 units/mL transfer set; use
separate set for
each vial.
Caffeine & RT 500 mg — 250 mg/mL RT NS 500 mg/ RT 24 hrs12 PI American
sodium benzoate 6 hrs (USP) 1000 mL12 Reg (2005);
12
Calcium chloride RT — — 100 mg/mL RT NS 10-13.3 mg/ RT 48 hrs24 PI Hospira
10% (1.36 mEq/ 6 hrs (USP) D5W mL24 (2009); 2; 24
mL) ≤20 mg/mL2 RT 24 hrs2
Calcium RT — — 100 mg/mL RT NS25 1-20 RT 24 hrs PI American
gluconate (0.465 4 hrs D5W25 mg/mL96,97,2 (2011); 2; 25;
10% mEq/mL) 96; 97
Candida albicans F — — — F Undiluted - F 24 hrs Send in TB syringe. PI Allermed
(Candin) 28 days (2000)
Caspofungin F SWFI/NS F NS ≤0.5 mg/mL F 48 hrs Refrigerate. PI Merck
(Cancidas) 70 mg 10.8 mL 7 mg/mL 1 hr 1/2NS/LR RT 24 hrs (2009)
(continued)
Cefazolin RT SWFI NS 20-40 mg/ F 14 days26,2 Defrosting frozen PI Sandoz
(USP)
(Kefzol) RT - 6 hrs D5W mL26 manufacturer product: (2006); PI
500 mg 2 mL 225 mg/mL RT 48 hrs26,2 Defrosted at RT = Baxter (2003);
10 gm 45 mL 200 mg/mL RT - 4 hrs 48 hrs PI Braun
Defrosted in refrig = (2012); 2; 26
1 gm 9.5 mL 100 mg/mL RT - 6 hrs Activated — RT 24 hrs 30 days
(USP)
Duplex F 7 dasy
33
Cefepime RT SWFI RT or F NS 1-40 mg/mL F 10 days33 Defrosting frozen PI Hospira
(Maxipime) NS/D5W 6 hrs (USP) D5W RT 48 hrs 33 manufacturer product: (2012); PI
500 mg 5 mL 100 mg/mL Defrosted at RT = Braun (2014);
24 hrs 33
1 gm 10 mL 100 mg/mL Activated — RT 12 hrs Defrosted in refrig =
2 gm 10 mL 160 mg/mL duplex F 5 dasy 7 days
Cefotaxime RT SWFI NS Diluted in up F 5 days Defrosting frozen PI Sanofi
(Claforan) 10 gm 47 mL 200 mg/mL RT - 4 hrs D5W/ to 1000 mL2 RT 24 hrs manufacturer product: (2007 &
D10W/LR Defrosted at RT = 2008); 2
1 gm 10 mL 95 mg/mL RT - 6 hrs 24 hrs
(USP)
2 gm 10 mL 180 mg/mL Defrosted in refrig =
10 days
Cefoxitin RT SWFI F NS 50-100 mL Defrosting frozen PI Bioniche
(Mefoxin) 1 gm 10 mL 95 mg/mL 4 hrs D5W 20 mg/mL5 F 13 days manufacturer product: (2009);
Defrosted at RT = PI Merck
2 gm 10 mL 180 mg/mL Other F 48 hrs 24 hrs (2002);
concentration RT 18 hrs Defrosted in refrig = PI APP (2008);
21 days PI Braun
Activated — RT 12 hrs
(2012); 2; 5
Duplex F 7d
Ceftaroline F SWFI/ F NS 50-250 mL F 24 hrs Total volume for PI Forest
(Teflaro) NS/D5W 6 hrs (USP) D5W 50 mL solutions (2013)
400 mg 20 mL 20 mg/mL RT 6 hrs
600 mg 20 mL 30 mg/mL
(continued)
Ceftazidime RT SWFI F NS Tazicef RT 24 hrs Defrosting frozen PI GLK (2006);
(Fortaz/Tazicef) 6 hrs (USP) D5W 1-40 mg/mL manufactured PI Hospira (2004);
1 gm 10 mL 100 mg/mL F 7d
product: PI Braun (2014)
2 gm 10 mL 170 mg/mL Fortaz RT 12 hrs Defrosted at RT =
1-40 mg/mL 8 hrs
F 3d
Defrosted in refrig =
6 gm 26 mL 200 mg/mL Activated — RT 12 hrs 3 days
duplex
F 3d
Ceftriaxone RT SWFI F NS 10-40 mg/mL F 10 d Defrosting frozen PI Sandoz (2010);
(Rocephin) 6 hrs (USP) D5W manufactured PI Roche (2004);
1 gm 9.6 mL 100 mg/mL RT 48 hrs
product: PI Braun (2013)
2 gm 19.2 mL 100 mg/mL Activated — RT 24 hrs Defrosted at RT =
duplex 48 hrs
F 7d
21 days
Cefuroxime RT SWFI F NS 1-30 mg/mL F 7d Defrosting frozen PI Westward
(Zinacef) 6 hrs (USP) D5W manufactured (2008);
750 mg 8.3 mL 90 mg/mL RT 24 hrs
product: PI GSK (2011)
1.5 gm 16 mL 90 mg/mL Defrosted at RT =
24 hrs
28 days
Certolizumab pegol F SWFI F – 24 hrs Undiluted For SubQ only. 400 mg dose requires 2 syringes/injections. PI UCB (2013)
(Cimzia)
200 mg 1 mL 200 mg/mL RT – 2 hrs Allow vial to reach room temp before reconstitution.
Use manufacturer-provided supplies for preparation.
Use 20G needle for reconstitution.
Do not shake.
Leave vial undisturbed for 30 min to fully reconstitute.
Draw solution into a separate syringe for each vial using a new
20G needle for each.
Replace 20G needle with 23G needle for SubQ administration.
(continued)
Drug Vial size Diluent Reconsti- Reconstitut- Infusion Dilution Fin- Compound- Comments References
tuted ed or opened solution specifics ished ed
vial concen- vial storage product IV stability
tration storage
Cetuximab F 100 mg — 2 mg/mL F Undiluted — F 12 hrs Low-sorbing PI BMS (2012)
(Erbitux) 200 mg — 2 mg/mL 6 hrs (USP) RT 8 hrs infusion set
with inline filter
used during
administration.
Chloramphenicol RT SWFI RT D5W ≤ 20 mg/mL2 RT 24 hrs98 May mix in PVC PI APP (2010);
(Chloromycetin) 1 gm 10 mL 100 mg/mL 6 hrs (USP)27 NS container28 2; 27; 28; 98
Undiluted2 — RT 48 hrs27
Chlorothiazide RT SWFI Use NS/D5W 1-2 mg/ RT 24 hrs Usually given as IV PI Akorn (2012);
(Diuril) 500 mg 18 mL 28 mg/mL immediately mL99,100 push. 99; 100
Undiluted — RT Use Mix in PVC-free
immediately container.
Chlorpromazine RT — — 25 mg/mL RT NS 0.05 mg/ RT 48 hrs103 For IV infusion PI Smithkline
28 days - mL103 (2002); 103
MDV
Ciprofloxacin RT 200 mg — 10 mg/mL RT NS 0.5-2 mg/ F 14 days104 Protect from light. PI Bayer (2011);
(Cipro) 400 mg — 10 mg/mL 6 hrs (USP) D5W mL104 104; 152
— — 2 mg/mL Diluted 2 mg/mL F 14 days152

(premix)
Cisatracurium F 200 mg — 10 mg/mL F NS 0.1-5 mg/ F 14 days6 PI Hospira
(Nimbex) 20 mg — 2 mg/mL 6 hrs - SDV D5W mL6 (2010); 1; 6
21 days –
10 mg — 2 mg/mL MDV
Clindamycin RT — — 150 mg/mL RT NS 6-12 mg/ F 14 days29,30 Max rate = PI Pharmacia
(Cleocin) 6 hrs (USP) D5W mL29,30 30 mg/min (2007); 29; 30
≤18 mg/mL RT or F 24 hrs
Colistimethate RT SWFI F NS, D5W No specifics F or RT 24 hrs EXP PI JHP (2013);
(Colistin) 150 mg 2 mL 75 mg/mL 6 hrs (USP) D5-1/2NS 13; 102
D5NS, LR
NS 3-4 mL102 F or RT 24 hrs
(inhalation) EXP13
(continued)
Conjugated F SWFI Use NS Unspecified RT Use Agitate vial gently; PI Wyeth
Estrogens 25 mg 5 mL 5 mg/mL immediately D5W immediately do not shake (2006)
(Premarin)
Cosyntropin RT NS RT Undiluted — RT 12 hrs2 PI Amphastar
(Cortrosyn) 0.25 mg 1 mL 0.25 mg/mL 6 hrs (USP) (2005); 2
Crotalidae F NS - RT NS 250 mL RT 4 hrs EXP Initial dose is PI Protherics

Polyvalent — 18 mL 4 hrs of typically 4-6 vials; (2000); 34
immune fab ovine reconstitution subsequent doses as
(CroFab) necessary.
SWFI Reconstitution with
— 25 mL 34 SWFI and hand
rolling/inverting may
be more rapid.34
Cyclosporine RT 250 mg — 50 mg/mL Use NS 20-100 mL RT 24 hours PVC-free or glass PI Novartis
(Sandimmune) immediately D5W only (2013)
Protect from light.
Low-sorbing
infusion set
with inline filter
used during
administration.
(continued)
Cytomegalovirus F 2.5 gm — 50 mg/mL F Undiluted — RT 12 hrs EXP Infusion to be PI Massa-
Immune globulin 6 hrs started within 6 chusetts Labs
(Cytogam) hrs vial entry, and (2004)
completed within
12 hrs.
Do not shake. Avoid
foaming.
Filter (0.22-15
micron) required;
Low-sorbing
infusion set
with inline filter
used during
administration.
Dantrolene RT SWFI RT Undiluted — RT 6 hrs Protect from light. PI P&G
(Dantrium) 20 mg 60 mL 0.33 mg/mL 6 hrs Incompatible with (1999)
D5W or NS
Do not use glass
bottle due to risk
of precipitate
formation.
(continued)
Daptomycin F NS F NS 50 mL Takes ~30 min to PI Cubist
(Cubicin) 500 mg 10 mL 50 mg/mL 6 hrs (USP) 20 mg/mL 35 F 10 days35 reconstitute. (2010); 35
Other RT 12 hrs BUD is time from

concentration F 48 hrs vial entry.
Undiluted — F 48 hrs Flush line with NS

before and after.
Deferoxamine RT SWFI RT NS No specifics RT 24 hrs PI Novartis
(Desferal) 500 mg 6 hrs (USP) D5W (2011)
95 mg/mL
IV/SubQ 5 mL
IM 2 mL 213 mg/mL
2 gm
IV/SubQ 20 mL 95 mg/mL
IM 8 mL 213 mg/mL
Desmopressin F 1 mL — 4 mcg/mL Use NS ≤10 kg – RT Use Stability data PI Sanofi
(DDAVP) immediately Use 10 mL immediately lacking (2007);
10 mL — 4 mcg/mL F diluent PI Teva (2009)
28 days >10kg –
Use 50 mL
diluent
Dexamethasone RT — — 4 mg/mL RT NS No specifics RT 24 hrs2 Protect from light. PI West-ward
sodium phosphate 10 mg/mL 6 hrs – SDV (2011); 2; 36
28 days –
Undiluted — RT 48 hrs36
MDV
Dexmedetomidine RT 200 mcg — 100 mcg/mL RT NS 4 mcg/mL37 RT 48 hrs37 PI Hospira
(Precedex) 6 hrs (USP) (2013); 37
Dexrazoxane RT SWFI F – 3 hrs LR 1.3-3 mg/mL F 4 hrs PI Pfizer
(Zinecard) 250 mg 25 mL 10 mg/mL RT – 30 min RT 1 hr (2012)
500 mg 50 mL 10 mg/mL
(continued)
Dianeal PD RT — — — 48 hrs No additive — RT 48 hrs Remove overfill plus PI Baxter
desired volume. (2015); 117
Additives — RT 24 hrs See PI for compatible
medications.
Digoxin Immune SWFI F Undiluted — F 4 hrs PI BTG (2012)
Fab (Digifab) 40 mg 4 mL 10 mg/mL 4 hrs
NS NS Not specified F 4 hrs

40 mg 36 mL 1 mg/mL
Dihydro- 1 mg — 1 mg/mL Use NS 100-250 RT Use Stability studies PI Novartis
ergotamine (DHE) immediately mL149 immediately lacking (2006); 149
Diltiazem F — — 5 mg/mL F NS 1 mg/mL F or RT 24 hrs PI Bedford
(Cardizem) 6 hrs (USP) D5W (2005)
Diphenhydramine RT — — 50 mg/mL RT NS, D5W 12.5- 50 mg F 14 days38 Protect from light. PI Abraxis
(Benadryl) 6 hrs (USP) in 50mL38 (2006); 38
Undiluted — F 14 days38
Dobutamine RT 250 mg — 12.5 mg/mL RT D5W TV 250 mL PVC-free bag40 PI Hospira
(Dobutrex) 500 mg — 12.5 mg/mL 6 hrs (USP) 1-5 mg/mL 39 F 14 days39,107 Protect from light. (2005);
PI Eli (1997);
Other RT 24 hrs May mix others in 39; 40; 106;
concentration PVC.106 107
NS TV 250 mL RT 24 hrs
Dolesetron RT 12.5 mg — 20 mg/mL RT NS/LR 50 mL F 48 hrs PI Sanofi-
(Anzemet) 100 mg — 20 mg/mL 6 hrs – SDV D5W/ RT 24 hrs Aventis (2011)
28 days – D5-1/2NS
500 mg — 20 mg/mL MDV Undiluted — RT 24 hrs
(continued)
Dopamine RT — — 12.5 mg/mL RT NS TV 0.4-3.2 mg/ RT 48 hrs41 Protect from light. PI American
6 hrs (USP) D5W TV mL41 (2009); 41
Other RT 24 hrs
concentration
Doripenem RT SWFI/NS RT NS 5 mg/mL F 72 hrs EXP PI Ortho-
(Doribax) 250 mg 10 mL 50 mg/mL 1 hr RT 12 hrs EXP McNeil (2012)
500 mg 10 mL 50 mg/mL D5W F 24 hrs EXP

RT 4 hrs EXP
Dornase alpha F 2.5 mg — 1 mg/mL Use Undiluted — RT 24 hrs Protect from light. PI Genentech
(Pulmozyme) immediately INHALATION (2014); 157;
ONLY 116
SWFI 5 mg in 30 RT Use Intrapleural injection

mL157,116 immediately
Doxycycline RT SWFI RT or F NS 0.1-1 mg/mL RT 48 hrs Protect from light. PI Bedford
hyclate 100 mg 10 mL 10 mg/mL 6 hrs (USP) D5W F 3 days (2012);
(Doryx) PI Fresenius
200 mg 20 mL 10 mg/mL (2013)
Eculizumab F 300 mg — 10 mg/mL F NS 5 mg/mL RT 24 hrs Infuse over 35 min. PI Alexion
(Soliris) D5W (2014)
Epinephrine HCL RT — — 1 mg/mL RT NS TV 0.001-0.03 RT 24 hrs Protect from light. PI JHP (2013);
(Adrenalin) 28 days – mg/mL150, 151 PI Hospira
MDV D5W TV 0.016-0.087 RT 24 hrs (2005); 7; 108;
mg/mL7,108 150; 151
Epoetin alfa F — — 10,000 Immediate- Undiluted — F 9 days (USP) Do not shake. PI Amgen
(Procrit) units/mL SDV (2011);
— — 20,000 F PI Centocor
units/mL 21 days – (2011)
MDV
— — 40,000
units/mL
(continued)
Epoprostenol RT Provided RT or F IV: 100 mL F 48 hrs EXP Protect from light. PI GSK (2011);
(Flolan) diluent 6 hrs (USP) Provided RT 8 hrs EXP Filter with 0.22 PI Teva (2008)
diluent micron.
0.5 mg 5 mL 0.1 mg/mL 24 hrs EXP Ice packs while
1.5 mg 5 mL 0.3 mg/mL with ice infusing (change
packs q2h)
Inhalation: 50 mL F 48 hrs EXP 1.5 mg/50 mL in
Provided AeroNeb Syringe
diluent RT 8 hrs EXP Filter with 0.22
micron
Protect from light.
Epoprostenol RT SWFI/NS RT or F SWFI/NS 100 mL F 8 days Protect from light. PI Actelion
(Veletri) 0.5 mg 5 mL 0.1 mg/mL 6 hrs (USP) TV RT 24 hrs (2012)
1.5 mg 5 mL 0.3 mg/mL

Ertapenem RT SWFI/NS RT or F NS ≤20 mg/mL F 24 hrs + Infuse over 30 min. PI Merck
(Invanz) 1 gm 10 mL 100 mg/mL 6 hrs 4 hrs after (2011)
removal
from fridge
RT 6 hrs
Erythromycin RT SWFI F NS 2-8.3 mg/ F 14 days109,42 Use at least 100 mL. PI Hospira
lactobionate 500 mg 10 mL 50 mg/mL 6 hrs (USP) mL109,42 Stable in D5W with (2011); 42;
(Erythrocin) sod bicarb added. 109
Esmolol RT 100 mg — 10 mg/mL RT NS/D5W/ 10 mg/mL RT or F 24 hrs If foil opened – 30 d PI Baxter

(Brevibloc) 6 hrs (USP) LR RT BUD125,119 (2014); 125;
Diluted 10 mg/mL RT 24 hrs 125,119 119
(premix) 20 mg/mL
Ethacrynate sod RT NS/D5W RT — 1mg/mL RT 24 hrs PI Aton (2007)
(Edecrin) 50 mg 50 mL 1 mg/mL 6 hrs (USP)
(continued)
Factor VIIa RT F Provided RT or F Undiluted — RT or F 3 hrs Inject against side PI Novo
(Novoseven) diluent 3 hrs of vial. (2014)
Gently swirl.
1 mg 1.1 mL 1 mg/mL
2 mg 2.1 mL 1 mg/mL
5 mg 5.2 mL 1 mg/mL
8 mg 8.1 mL 1 mg/mL
Famotidine F 20 mg — 10 mg/mL F NS 0.2 mg/mL43 F 14 days43 May be given PI Pfizer
(Pepcid) 6 hrs – SDV D5W undiluted. (2011); 43
28 days – Other RT 48 hrs For premixed
MDV concentration bag, follow mfg
expiration.
Fenoldopam F 10 mg — 10 mg/mL Use NS 40 mcg/mL RT 24 hrs PI Hospira
(Corlopam) RT 20 mg — 10 mg/mL immediately D5W (2005)
Fentanyl RT 250 mcg — 50 mcg/mL RT NS (PCA) 10 mcg/mL F 14 days111 PI Hospira

(Sublimaze) 2500 — 50 mcg/mL 6 hours Undiluted — F 14 days 110 (2008);
mcg 110;111
Ferric RT 750 mg — 50mg/mL RT NS 2-4 mg/mL RT 48 hrs Do not dilute to < 2 PI American
carboxymaltose 6 hrs mg/mL. (2013)
(Injectafer)
Ferrlecit RT 62.5 mg — 12.5 mg/mL Use NS 100 mL RT Use PI Sanofi
(sodium ferric immediately Undiluted — immediately (2011)
gluconate
complex)
Filgrastim F 300 mcg — 300 mcg/ RT D5W ≥5 mcg/mL F 24 hrs EXP For conc. 5-15 mcg/ PI Amgen
(Neupogen) 480 mcg — mL 6 hrs (USP) Undiluted F 14 days (USP) mL, albumin must (2015)
be added for final
conc. of 0.2% (2
mg/mL).
Avoid shaking.
(USP)
Fluconazole RT — — 2 mg/mL — Diluted 2 mg/mL RT 48 hrs If foil opened – 30 d PI Pfizer
(Diflucan) (premix) RT BUD144 (2008); 144
(continued)
Folic acid RT 50 mg — 5 mg/mL RT NS or 50 mL RT 24 hrs Protect from light.2 PI APP (2008);
28 days – D5W44 ≤5 mg2 2; 44
MDV May be added
to maintenance
solutions (D20W, fat
emulsion 10%).2
Fomepizole RT 1.5 gm — 1 gm/mL RT or F NS/D5W ≥100 mL2 RT or F 24 hrs2 If fomepizole 2; PI Orphan
(Antizol) 6 hrs solidifies, can be (2000); PI
liquefied by running Paladin (2009)
vial under warm
water or by holding
in hand.2
Fosaprepitant F NS RT or F NS 110/145 mL RT 24 hrs Do NOT shake PI Merck
(Emend) 115 mg 5 mL 23 mg/mL 6 hrs (USP) 1 mg/mL or tube, due to (2012)
150 mg 5 mL 30 mg/mL excessive foaming.
Foscarnet RT 6000 mg — 24 mg/mL RT NS Peripheral F 14 days45 Compatible with PI AstraZeneca

(Foscavir) 6 hrs (USP) D5W 12 mg/mL PVC containers. (2005); 45
Undiluted Central line RT 24 hrs Protect from light45
24 mg/mL
Fosphenytoin F — — 50 mg PE/ RT or F NS 1-20 mgPE/ F 14 days46 PI Parke-Davis
(Cerebyx) mL 6 hrs (USP) D5W mL46 RT 48 hrs 46 (2011); 46
Furosemide RT — — 10 mg/mL RT NS 1.2-3.2 mg/ F 9 days (USP)47 Protect from light. PI American
(Lasix) 6 hrs (USP) mL47 (2001); 2; 47
1-10 mg/mL2 RT 24 hrs2
D5W 1-10 mg/mL2 RT 24 hrs2
Ganciclovir RT SWFI RT NS/D5W ≤10 mg/mL F 14 days PI Roche
(Cytovene) 500 mg 10 mL 50 mg/mL 6 hrs (USP) LR (2008)
Gentamicin RT — — 40 mg/mL F NS 50-100 mL F 48 hours48,2 PI APP (2008);

(Garamycin) 28 d – MDV D5W PI Hospira
6 hrs – SDV (2004); 2; 48
Glucagon RT SWFI Use D5W49 0.1 mg/mL RT Use Stability studies PI Bedford
(GlucaGen) 1 mg 1 mL 1 mg/mL immediately NS49 immediately2 lacking (2013); PI Eli
(2005); 2; 49
(continued)
Granisetron RT 1 mg — 1 mg/mL RT NS 25-50 mL RT 24 hrs Can be given PI Genentech
(Kytril) 28 days – D5W undiluted IV push (2011)
MDV Undiluted — RT 24 hrs over 30 sec, or
6 hrs – SDV IV infusion over
5-10 min.
Haloperidol RT 5 mg — 5 mg/mL RT D5W 1 mg/mL50 RT 30 hrs (USP)50 Verify product name PI Ortho-
lactate 50 mg — 5 mg/mL 6 hrs (USP) (decanoate should McNeil
(Haldol) NOT be given IV (2010); 50
route).
Protect from light.
Do not dilute in NS.
PVC-free bags50
Hemin RT SWFI Use Undiluted — RT Use 0.45-micron or PI Ovation
(Panhematin) 313 mg 43 mL 7 mg/mL immediately immediately2 smaller in-line (2005); 2
filter recommended
during
administration.
Heparin RT — — Variable RT D5W 10-40 units/ RT 48 hrs112,8 PI APP (2008);
28 days – mL112,8 PI Baxter
MDV 40-100 RT 24 (2006); 2, 8;
6 hrs – SDV units/mL2 hrs113,114,115 112; 113; 114;
115; 56; 118
NS 1-40 units/ RT 48 hrs112,8
mL112,8
1 units/mL112 F 9 days(USP)112
40-100 RT 24
units/mL2 hrs113,114,115
Plasmalyte ≤40 units/ RT 24 hrs56,118
A/ mL56
Normosol R
(continued)
Drug Vial size Diluent Reconstituted Reconstituted Infusion Dilution Finished Compound- Comments References
vial concen- or opened solution specifics product ed
tration vial storage storage IV stability
Hyaluronidase F 150 unit — 150 units/ Use NS 15 units/mL RT 6 hrs Prepare in 1 mL PI Halozyme
(Hylenex) mL immediately slip-tip syringe. (2012)
Hydrocortisone RT Act-o- Provided RT or F NS 250-1000 mL Protect from light. PI Pharmacia
(Solu-Cortef) vial 6 hrs (USP) D5W RT 24 hrs2 (2014); 2; 51
100 mg — 50 mg/mL D5NS ≤1 mg/mL2
250 mg — 125 mg/mL >1 - 60 mg/ RT 4 hrs2
500 mg — 125 mg/mL mL2
1000 mg — 125 mg/mL

BSWI Undiluted — 48 hrs (USP)51
100 mg 2 mL 50 mg/mL
Hydromorphone RT 50 mg — 10 mg/mL Use NS (PCA) 30 mL F 14 days111, 120 PI Purdue
(Dilaudid) immediately 10 mg/mL 111 (2011); 111;
120
Hydroxy- RT 1250 mg — 250 mg/mL RT Undiluted — RT Use For IM injection PI Ther-RX
progesterone 28 days (USP) immediately only. (2011)
caproate Protect from light.
(Makena)
Keep in original box
and keep upright.
Ibutilide fumarate RT 1 mg — 1 mg/10 mL RT or F NS 50 mL RT 24 hrs PI Pharmacia
(Corvert) 6 hrs (USP) D5W F 48 hrs (2002)
Imipenem- RT SWFI RT NS 100-250 mL2 F 24 hrs Rinse vial to ensure PI Merck

Cilastatin 250 mg 5 mL 50 mg/mL 4 hrs D5W ≤ 5 mg/mL 2
RT 4 hrs complete transfer of (2009); 2
(Primaxin) drug.
500 mg 10 mL 50 mg/mL
(continued)
Immune globulin Do not shake. PI Grifols
(IVIG) Foams up easily. (2010);
Gamunex F — — 10% Use Undiluted — RT 6 months BUD is for sending PI Baxter
immediately vials (2012);
Flebogamma RT — — 5%/10% Use Undiluted — RT Exp Date PI Talecris
immediately (2010);
PI Octapharma
Privigen RT — — 10% Use Undiluted — RT Exp Date (2014);
immediately PI CSL (2007)
Gammagard RT — — 5%/10% Use Undiluted — RT Exp Date
immediately
Octagam F — — 5%/10% Use Undiluted — RT 12 months
immediately from date of
manufacture
Indomethacin RT NS/SWFI Use Undiluted — RT 30 hrs (USP)52 Protect from light. PI Fresenius
(Indocin) 1 mg 1 mL 0.1 mg/ immediately (2014); 52
0.1 mL
Infliximab F SWFI F NS 250 mL F 24 hrs153 Mix in Non-PVC or PI Janssen
(Remicade) 3 hrs glass (2011); 153
100 mg 10 mL 10 mg/mL 0.4-4 Do not shake.
mg/mL Attach low-sorbing
infusion line
w/ low-protein
binding filter upon
administration.
Insulin, regular F 1000 — 100 units/ F NS 1 unit/mL54 F 7 days54 PI Novo
(Humulin R-100) units mL 28 days (2012);
(Novolin R-100) 0.1-1 unit/mL F 48 hrs then PI Lilly (2013);
(Humulin) 54
RT 48 hrs
0.05-1 unit/ RT 24 hrs
mL
(Novolin)
Insulin glargine/ F — — 100 units/ F Syringe — F 9 days (USP) PI Sanofi
detemir mL 28 days (2013);
(Lantus) PI Novo
(Levemir) (2015)
(continued)
Insulin F — — 100 units/ F Syringe — F 9 days (USP) PI Eli (2007);
(Humalog 50/50) mL 28 days PI Lilly (2005);
(Humulin 70/30) PI Novo
(Novolog 70/30) (2007)
(Humalog 75/25)
Iron dextran RT 100 mg — 50 mg/mL RT NS (test Unspecified RT 6 hrs EXP55 PI American
(Infed, 6 hrs (USP) dose) (2008);
Dexferrum) NS 250-1000 PI Watson
(infusion) mL2 (2009); 55; 2
Iron sucrose RT 100 mg — 20 mg/mL RT NS 1-10 mg/mL RT 48 hrs May give 200 mg PI American
(Venofer) 6 hrs Undiluted — F 7 days slow IV push. (2012)
Isoproterenol RT 1 mg — 0.2 mg/mL Use D5W TV 0.004 mg/mL RT 24 hrs56,57 Protect from light. PI Hospira
(Isuprel) immediately (2004); 56; 57
Ketamine RT — — 50 mg/mL RT NS/D5W/ 1-2 mg/mL RT 48 hrs147, 148 Protect from light. PI JHP (2013);
— — 100 mg/mL 6 hrs - SDV SWFI 147; 148
28 days –
MDV
Ketorolac RT 15 mg — 15 mg/mL RT NS 0.3-0.6 mg/ F 14 days PI Bedford
(Toradol) — — 30 mg/mL 6 hrs (USP) mL121 (2009); 121
Labetalol RT 200 mg — 5 mg/mL RT Undiluted — RT 30 hrs (USP) PI Prometheus

(Trandate) 28 days (USP) D5W 1.25-3.75 F 3 days (2010); 9
mg/mL9
Lacosamide RT 200 mg N/A 10 mg/mL RT NS/D5W/ 50 mL RT 24 hrs C-V PI UCB (2014)
(Vimpat) 6 hrs (USP) LR
Undiluted — RT 30 hrs (USP)
(continued)
Leucovorin RT SWFI Use D5W 0.1-1.5 mg/ F 4 days58 Protect from light. PI Teva
calcium 50 mg 5 mL 10 mg/mL immediately (preferred) mL58 Max infusion rate: (2007); 58
160 mg/min.
100 mg 10 mL 10 mg/mL NS 1-1.5 mg/ F 4 days58 May use BSWI
200 mg 20 mL 10 mg/mL mL58 (benzyl alc) to
reconstitute vial if
500 mg 50 mL 10 mg/mL total dose <10 mg/
350 mg 17.5 mL 20 mg/mL m2. Refer to PI for
BUD.
Levetiracetam RT 500 mg N/A 100 mg/mL RT NS/D5W/ 100 mL RT 24 hrs PI UCB (2013)
(Keppra) 6 hrs (USP) LR ≤15 mg/mL
Levoleucovorin F 175 mg — 10 mg/mL RT NS or D5W 0.5-5 mg/mL RT 4 hrs Typically dosed PI Spectrum
(Fusilev) 250 mg — 10 mg/mL 6 hrs (USP) at one-half usual (2011)
RT NS RT NS 0.5-5 mg/mL RT 12 hrs dose of racemic
4 hrs leucovorin.
50 mg 5.3 mL 10 mg/mL D5W 0.5-5 mg/mL RT 4 hrs
Levothyroxine RT NS RT or F NS 250 mL RT 12 hrs59 Protect from light. PI APP (2012);
(Synthroid) 100 mcg 5 mL 20 mcg/mL 4 hrs 0.4-2 mcg/ 59; 14
200 mcg 5 mL 40 mcg/mL mL59
500 mcg 5 mL 100 mcg/mL Undiluted — F 7 days14

Lorazepam F — — 2 mg/mL F D5W TV 1 mg/mL60 RT 24 hrs60 C-IV PI Akorn
(Ativan) 28 days (USP) May mix in PVC 60,61 (2008); 60; 61
(USP)
Magnesium RT — — 50% RT D5W ≤200 mg/mL RT 48 hrs Multiple vial PI Hospira
122,123,124
sulfate (0.5 g/mL) 6 hrs (USP) NS concentrations (2009); 122;
(4.06 mEq/ LR are commercially 123; 124
mL) available, check
label carefully.
(continued)
Mannitol RT — — — RT Undiluted RT 30 hrs (USP) Always use filter PI Abraxis
6 hrs (USP) when mixing. (2006)
If there are any
crystals present in
the solution, they
must be completely
dissolved before use.
Meperidine RT — — — RT NS (PCA) 30 mL F 14 days111 PI Hospira
(Demerol) 6 hrs (USP) 10 mg/mL111 (2005); 111
Meropenem RT SWFI F NS 2.5-20 F 24 hrs PI AstraZeneca

(Merrem) 500 mg 10 mL 50 mg/mL 6 hrs (USP) mg/mL RT 4 hrs (2013)
1 gm 20 mL 50 mg/mL D5W 2.5-20 F 6 hrs

mg/mL RT 1 hr
Mesna RT 1 gm — 100 mg/mL RT NS 20 mg/mL RT 24 hrs If mixed with PI Baxter
(Mesnex) 8 days – D5W ifosfamide in (2014)
MDV the same IV bag,
do not exceed a
final ifosfamide
concentration of 50
mg/mL.
Methocarbamol RT 1 gm — 100 mg/mL RT NS62 ≤15.4 mg/ RT 48 hrs(USP)62 Max dose: 3 g/day PI Baxter
(Robaxin) 6 hrs (USP) D5W62 mL126 for no more than 3 (2003); 62;
consecutive days. 126
May repeat after
drug-free interval of
48 hrs.
Undiluted — RT 6 hrs Contains
polyethylene glycol.
Methyldopate RT 250 mg — 50 mg/mL RT D5W 100 mL2 RT 24 hrs127 PI American
(Aldomet) 6 hrs (USP) (2005); 2;127
(continued)
Methylene blue RT 100 mg — 10 mg/mL RT NS 50 mL63 RT Use For vasoplegia PI American
6 hrs (USP) D5W immediately (cardiac surg), (2011); 63
Undiluted — RT Use ifex-induced
immediately encephalopathy,
methemoglobinemia
Methyl- RT Act-o- Use only RT NS 0.3-30 RT 24 hrs64 Follow package PI Pharmacia
prednisolone vial supplied 62.5 mg/mL 6 hrs mg/mL64 directions. Several (2011); 64
(Solu-Medrol) 125 mg diluent (PF different PF and
or BWFI formulations) preserved (benzyl
500 mg with 125 mg/mL D5W 0.3-1 mg/ RT 24 hrs64 alc) formulations
1 gm benzyl 125 mg/mL RT mL64 available, with
alc. for 48 hrs varying instructions
reconstitu- (benzyl alc) for use.
tion ≥1-30 mg/ 8 hrs64 If PF needed
Vial mL64 (pediatric or high
dose >2 gm), use PF
500 mg 62.5 mg/mL Undiluted — RT 48 hrs act-o-vial.
1 gm 62.5 mg/mL
2 gm 65.4 mg/mL
Metoclopramide RT — — 5 mg/mL RT NS or D5W 0.2-3.2 RT 24 hrs65 PI Baxter
(Reglan) 6 hrs (USP) mg/mL65 (2009); 65; 66
Undiluted — RT 48 hrs66
Metronidazole RT 500 mg — 5 mg/mL Use Undiluted 5 mg/mL68 RT 48 hrs (USP)68 Split premix bag PI Baxter
(Flagyl) immediately for 250 mg/50 mL (2009); 67; 68
doses.
Light protection not
required.67
Micafungin RT NS/D5W RT NS 100 mL RT 24 hrs Protect from light. PI Astellas
(Mycamine) 50 mg 5 mL 10 mg/mL 6 hrs (USP) D5W Do not vigorously (2011)
100 mg 5 mL 20 mg/mL shake vial during

reconstitution, to
reduce foaming.
(continued)
Midazolam RT 50 mg — 5 mg/mL RT D5W TV 50 or 100 mL F 14 days128 Protect from light. PI Novaplus
(Versed) 6 hrs (USP) 1 mg/mL 128 (2004); 128
Milrinone RT 50 mg — 1 mg/mL RT NS 0.2-0.4 F 14 days69,70 Premix 20 mg/100 PI Hospira

(Primacor) 6 hrs (USP) D5W mg/mL69,70 mL available (2007);
PI Sanofi
(2007);69;70
Morphine RT 100 mg — 10 mg/mL RT NS TV 100 mL RT 48 hrs129, 130 PI Hospira
6 hrs (USP) D5W TV 1 mg/mL 2
F 7 days 129, 130 (2004); 2; 129;
130
Mycophenolic RT D5W RT D5W 6 mg/mL RT 4 hrs PI Roche
acid (Cellcept) 500 mg 14 mL 33 mg/mL 4 hrs (2009)
MVI F — — Vial 1: 5 mL Use NS 500-1000 mL F 24 hrs Protect from light. PI Baxter

(Infuvite + immediately D5W (2004); PI
Adult) Vial 2: 5 mL Sandoz (2007)
(Infuvite F — — Vial 1: 4 mL Use NS >100 mL F 24 hrs
Pediatric) + immediately D5W
Vial 2: 1mL
Nafcillin RT SWFI/NS RT NS 10-200 F 7 days Defrosting frozen PI Sandoz
(Unipen) 1 gm 3.4 mL 250 mg/mL 6 hrs – SDV mg/mL manufacturer (2004); PI
(USP)
product: Baxter (2011);
2 gm 6.6 mL 250 mg/mL 4 hrs –10 gm D5W 10-30 RT 24 hrs Defrosted at RT = PI Sagent
10 gm 93 mL 100 mg/mL vial mg/mL 72 hrs (2012)
Defrosted in refrig
= 21 days
Naloxone RT — — 0.4 mg/mL RT NS 0.004-0.04 RT 24 hrs PI Hospira
(Narcan) — — 1 mg/mL 6 hrs (USP) D5W mg/mL (2008)
Natalizumab F 300 mg — 20 mg/mL Use NS 100 mL RT or F 8 hrs Do not shake. PI Biogen Idec
(Tysabri) immediately (2013)
(continued)
Neomycin/ F 1 mL — Neomycin F NS 1 Liter F 48 hrs2 For irrigation PI Pfizer
Polymixin 20 mL — 40 mg/mL 28 days - (2003); 2
(Neosporin) Polymyxin MDV
B 200,000
units/mL
1 mg — 1 mg/mL
Nesiritide RT NS/D5W RT or F NS 6 mcg/mL RT 48 hrs Do not shake. PI Scios
(Natrecor) 1.5 mg 5 mL 0.32 mg/mL 6 hrs(USP) D5W (2012), 101
Nicardipine RT 25 mg — 2.5 mg/mL RT NS 0.05-0.5 mg/ RT 48 hrs154 PI EKR

(Cardene) 6 hrs (USP) D5W mL154 (2010); 154
Nitroglycerin RT 50 mg — 5 mg/mL RT D5W TV 0.2-0.4 mg/ RT 48 hrs (USP)71 Glass bottle or PVC- PI Abbott
6 hrs (USP) mL71 free bag (1999);
F 14 days(USP)71 Protect from light PI American
(2002); 71; 2
0.05-0.2 mg/ F 7 days2 Nitronal (FDA-
mL2 (glass only) permitted import) is
chemically identical
to NTG, but
concentration is 1
mg/mL.
Nitroprusside RT 50 mg — 25 mg/mL RT D5W 50-200 mcg/ RT 24 hrs Protect from light. PI Hospira
(Nipride, 6 hrs (USP) mL (2004); PI
Nitropress) Abbott (1998)
Norepinephrine RT 4 mg — 1 mg/mL RT D5W TV 0.016-0.064 F 14 days72,73 Protect from light. PI Sicor
(Levophed) 6 hrs (USP) mg/mL72,73 (2005); 72;
73; 74
RT 48 hrs72,74
NS TV 0.004-0.064 RT 48 hrs73,74
mg/mL73,74
(continued)
Drug Vial size Diluent Reconsti- Reconstitut- Infusion Dilution Finished Compounded Comments References
tuted ed or opened solution specifics product IV stability
tration
Obinutuzumab F 1000 mg — 25 mg/mL F NS 0.4-4 mg/mL F 24 hrs IVPB may be stored PI Genentech
(Gazyva) 6 hrs (USP) See (see up to 24 hr refrig (2013)
comments comment) followed by 48 hr
RT (incl. infusion
time)
Do not shake or
freeze.
C1D1: 100 mg/100
mL
C1D2: 900 mg/250
mL
Subsequent doses:
1000 mg/250 mL
Octreotide F — — 50 mcg/mL F NS 50-200 mL RT 24 hrs MDV- Protect from PI Novartis
(Sandostatin) 6 hrs – SDV D5W light. (2008)
— — 100 mcg/ 14 days –
mL MDV
— — 200 mcg/
mL
— — 500 mcg/
mL
— — 1000 mcg/
mL
Ondansetron RT 4 mg — 2 mg/mL RT NS or D5W 50 mL PI GSK
(Zofran) 40 mg — 2 mg/mL 6 hrs – SDV 0.024-0.6 RT 48 hrs (2012); 75; 76;
28 days – mg/mL75,76,131 77; 131
MDV F 14
days75,76,131
Other RT 48 hrs
concentration
Undiluted — RT 48 hours77
(continued)
tration
Oprelvekin F Provided F or RT Undiluted 5 mg/mL F or RT 3 hrs For SubQ injection. PI Wyeth
(Neumega) SWFI 3 hrs Available as a 5 mg (2009)
syringe kit.
5 mg 1 mL 5 mg/mL Do not shake.
Oxacillin RT SWFI/NS RT NS NS D5W, LR - shorter PI Sandoz
6 hrs – SDV (preferred) stability, refer to PI. (2009); PI
1 gm 10 mL 100 mg/mL 4 hrs – 10 D5W, 10-100 mg/ RT 48 hrs (USP) Defrosting frozen Baxter (2011)
gm D5NS, LR mL manufacturer
2 gm 20 mL 100 mg/mL F 7 days
product:
10 gm 93 mL 100 mg/mL Defrosted at RT =
48 hrs
21 days
Oxychlorosene F 2 gm — — Use NS 0.1-0.6% F 10 days For irrigation 132
(Clorpactin) immediately SW
Oxytocin RT — — 10 units/mL RT LR 0.02-0.05 F 14 days134 PI Sicor
(Pitocin) 6 hrs – SDV units/mL133 (2006); PI JHP
28 days – NS <0.08 unit/ F 14 days134 (2011); 133;
MDV mL134 134
Palivizumab F 50 mg — 100 mg/mL Use Undiluted — Use 6 hrs Do not dilute. Do PI

(Synagis) immediately imme- not shake. MedImmune
100 mg — 100 mg/mL diately IM injection (2009)
volumes >1 mL
should be given as
divided dose.
Dispense in 1mL
syringe with 25
gauge safety glide
needle.
Pamidronate RT SWFI F NS, D5W 250-1000 mL RT 24 hrs PI Novartis
(Aredia) 30 mg 10 mL 3 mg/mL 6 hrs (USP) 1/2NS (2008)
90 mg 10 mL 9 mg/mL
(continued)
tration
Pantoprazole RT NS RT NS, LR 0.4-0.8 mg/ F 14 days135 Protect from light.135 PI Wyeth
(Protonix) 40 mg 10 mL 4 mg/mL 6 hrs D5W mL135 (2007); 135
Papaverine RT 60 mg — 30 mg/mL RT NS/D5W/ Not specified RT 24 hrs Protect from light. PI Parenta
300 mg — 30 mg/mL 6 hrs – SDV SWFI (2006);
28 d - MDV PI American
(2009); 1; 2
Pegloticase F 8 mg — 8 mg/mL Use NS or ½NS 250 mL F 4 hrs Protect from light. PI Savient
(Krystexxa) immediately Do not shake. (2010)
Penicillin G RT SWFI F 50-100 mL Defrosting frozen PI Pfizer

potassium 5 MU 8 mL 500,000 6 hrs (USP) NS 20,000- F 14 days manufactured (2005)
units/mL 100,000 product: PI Sandoz
RT 48 hrs Defrosted at RT = (2009);
units/mL136,137
24 hrs 136;137
20 MU 33 mL 500,000 D5W Unspecified F or RT 24 hrs138 Defrosted in refrig = PI Baxter
units/mL 14 days (2012); 138
Pentamidine SWFI RT Undiluted — RT 48 hrs Check for correct PI APP (2002)
(Nebupent) – RT 300 mg 6 mL 50 mg/mL 6 hrs (USP) product (injection
Inhalation vs. inhalation)
(Pentam) – IV/IM SWFI/ RT D5W 50-250 mL RT 24 hrs Mfg: Reconstituted
RT D5W 6 hrs (USP) solution to be
300 mg 3 mL 100 mg/mL protected from light,
but not required for
dilution.
Pentobarbital RT 1000 mg — 50 mg/mL RT NS 0.6-1.25 mg/ RT 12 hrs79 C-II PI Lundbeck
(Nembutal) 2500 mg — 50 mg/mL 28 days – D5W mL79 Max rate of admin (2009); 78;
MDV 50 mg/min 79; 80
4-8 mg/mL78 RT 24 hrs78
Undiluted - RT 48 hrs80
(continued)
tration
Phenobarbital RT 65 mg — 65 mg/mL RT NS 0.32-10 mg/ RT 24 hrs C-IV PI Hospira
130 mg 130 mg/mL 6 hrs (USP) mL140,141 Max rate of (2008); 139;
admin: 60 mg/min 140; 141
(adults)139
D5W/LR Unspecified RT Use Stability studies
immediately lacking
May be given
undiluted
Phenylephrine RT 10 mg — 10 mg/mL RT NS 0.02-0.1 mg/ F 24 hrs Protect from light. PI Eclat
(Neo-Synephrine) 6 hrs – 1 mL mL (2014); PI
50 mg — 10 mg/mL vial 0.1-0.2 mg/ RT 48 hrs142 West-Ward
4 hrs - PBV mL142 (2013); 142;
11
0.2-2.5 mg/ RT 24 hrs11
mL11
100 mg — 10 mg/mL D5W 0.02-0.1 mg/ F 24 hrs
mL
Phenytoin RT 100 mg — 50 mg/mL RT NS ≥ 5 mg/mL RT 4 hrs EXP Do not refrigerate, PI Pfizer
(Dilantin) 6 hrs (USP) due to precipitation. (2011)
250 mg — 50 mg/mL Max rate of admin
50 mg/min
Phytonadione RT 1 mg — 2 mg/mL Use NS ≥ 50 mL RT Use Protect from light. PI Merck
(Vitamin K) 10 mg 10 mg/mL immediately D5W immediately Max IV rate = 1 mg/ (2002)
min
Recommended
infusion time ≥ 20
min.
Stability data
lacking
(continued)
tration
Piperacillin / RT SWFI/NS/ RT NS 50-150 mL RT 24 hrs Defrosting frozen PI Wyeth
Tazobactam D5W 6 hrs (USP) D5W F 7 days manufactured (2007)
(Zosyn) 10 mL 225 mg/mL product:
2.25 gm
*Combined Defrosted at RT =
components* 3.375 15 mL 225 mg/mL 24 hrs
gm Defrosted in refrig
4.5 gm 20 mL 225 mg/mL = 14 days
40.5 gm 152 mL 225 mg/mL
Plerixafor RT 24 mg — 20 mg/mL RT Undiluted — RT 48 hrs For SubQ injection PI Genzyme
(Mozobil) 6 hrs (USP) Prepare in TB (2008); 143
syringe.
Potassium acetate RT — — 2 meq/mL RT NS — RT 24 hrs Stability studies PI Hospira
— — 4 meq/mL 4 hrs – PBV D5W lacking (2010); PI
28 days – American
MDV (2005); 2
Potassium RT — — 2 mEq/mL RT NS56 ≤ 80 mEq/L81 RT 24 hrs56 Stability studies PI Hospira
chloride 6 hrs – SDV D5W56 lacking (2004); 81; 56
28 days – LR56
MDV
Potassium RT — — 3 mmol/mL RT NS25 — RT 24 hrs145 For American PI American
phosphate 6 hrs – SDV D5W25 Regent (ARI) (2011); 25;
28 days – product only: 145
MDV 5 micron filter
required during
admixture, &
0.22 micron
inline filter during
administration
Stability studies
lacking
(continued)
tration
Pralidoxime RT SWFI Use Undiluted — PI Baxter
(Protopam) IM immediately (2010)
1000 mg 3.3 mL 300 mg/mL
IV Use NS 100 mL
1000 mg 20 mL 50 mg/mL immediately 10-20 mg/mL
Prismasate RT — — — 24 hrs — 0-4.5 mEq/L RT 6 hrs Mix both PI Gambro
Mag+Ca54 compartments 2015; 54
prior to addition of
calcium.
BUD if calcium
added = 6 hrs54
BUD if no calcium
added = 24 hrs
Procainamide RT — — 100 mg/mL RT NS or D5W 20 mg/mL RT Use Slight color change PI Hospira
(Procan) 28 days LD immediately to yellow can occur; (2004); 10;
500 mg/mL NS 2-4 mg/mL82 RT 24 hrs82 solutions darker 82; 83
(Preferred) MD than light amber
F 7 days82 should be discarded.
D5W 1-2 mg/ RT 8 hrs10,83
mL10,83
Promethazone RT 25 mg — 25 mg/mL Use D5W ≤25 mg/mL RT 24 hrs2 Protect from light.2 PI Teva
(Phenergan) 50 mg — 50 mg/mL immediately NS (2009); 2
Protamine RT — — 10 mg/mL RT D5W Not specified RT Use PI APP (2008)

6 hrs – SDV NS immediately
28 days –
MDV
Prothrombin Provided RT Undiluted — RT 4 hrs PI CSL
complex human SWFI (Refer to 4 hours Behring (2013)
(Kcentra) — 20 mL carton)
20-31 units/
mL
(continued)
tration
Pyridoxine RT 100 mg — 100mg/mL RT NS Not specified RT Use Protect from light.146 2; 146
28 days D5W immediately Stability studies
lacking
Quinidine RT 800 mg — 80mg/mL RT Arrhythmia 50 mL RT 24 hrs 15 mg quinidine PI Lilly (2012)
gluconate 28 days D5W 16 mg/mL F 48 hrs base = 24 mg
quinidine gluconate
Malaria 250 mL RT 24 hrs
NS F 48 hrs
Quinupristin- F SWFI/ RT D5W 100-750 mL F 54 hrs Do not shake. PI DSM
Dalfopristin D5W 30 min (2010)
(Synercid) 500 mg 5 mL 100 mg/mL RT 5 hrs
Ramucirumab F 100 mg — 10 mg/mL F NS 250 mL F 24 hrs Do not shake. PI Lilly (2014)
(Cyramza) 500 mg — 10 mg/mL 6 hrs (USP) RT 4 hrs Keep the vial in
original carton to
protect from light.
Attach/send with
low-sorbing infusion
line w/ low-protein
binding filter. (a)
Ranitidine RT 50 mg — 25 mg/mL RT or F NS ≤2 mg/mL F 14 days PI GSK (2015)
(Zantac) F 6 hrs (USP) D5W
Rasburicase F Provided F NS TV 50 mL F 24 hrs Do not bolus, shake PI Sanofi

(Elitek) 1.5 mg 1 mL 1.5 mg/mL 6 hrs (USP) or filter. (2009)
7.5 mg 5 mL 1.5 mg/mL

Rifampin RT SWFI RT D5W 100 mL–30 RT 4 hrs Protect from light. PI Aventis
(Rifadin) 6 hrs (USP) min (2013)
500 mL-3 hr
600 mg 10 mL 60 mg/mL NS 100 mL–30 RT 24 hrs
min
500 mL-3 hr
Rituximab F 100 mg — 10 mg/mL F NS 1-4 mg/mL F 24 hrs Do not shake. PI Genentech
(Rituxan) 500 mg — 10 mg/mL 6 hrs (USP) D5W (2012)
(continued)
Drug Vial size Diluent Reconsti- Reconsti- Infusion Dilution Finished Compounded Comments References
tuted tuted or solution specifics product IV stability
vial concen- opened storage
tration vial storage
Rocuronium F 50 mg — 10 mg/mL F NS ≤ 5 mg/mL RT 24 hrs PI Organon
(Zemuron) 100 mg — 10 mg/mL 28 days – D5W (2008)
MDV LR
6 hrs – SDV
Romiplostim F SWFI F or RT Undiluted — F or RT 24 hrs For SubQ injection PI Amgen
(Nplate) 6 hrs (USP) only. (2013)
250 mcg 0.72 mL 500 mcg/mL Protect from light.
Do not shake.
500 mcg 1.2 mL 500 mcg/mL Reconstitution takes
~2 min.
Use 1 mL luer-lock
syringe with 0.01
mL markings.
Sargramostim F SWFI/ SWFI: NS No specs but F or RT 48 hrs Do not shake. Do PI Bayer
(Leukine) BWFI F – 6 hrs if <10 mcg/ not use filter. (2008)
250 mcg 1 mL 250 mcg/mL mL If final conc <10
500 mcg 1 mL 500 mcg/mL BWFI or See mcg/mL, albumin at
500 mcg — 500 mcg/mL liquid: comments a final conc of 0.1%
F – 20 days Undiluted — F SWFI: 6 hrs should be added
(SubQ) BWFI: 9 to saline prior to
days addition of Leukine.
Refer to PI.
Secretin, human FR NS Use Undiluted — RT Use Store vials in freezer. PI ChiRhoClin
(Chirostim) 16 mcg 8 mL 2 mcg/mL immediately immediately Protect from light. (2006)
Sincalide RT SWFI RT NS1 30-100 mL RT 8 hrs PI Bracco

(Kinevac) 5 mcg 5 mL 1 mcg/mL 6 hrs (USP) (1994); 1
Sodium acetate RT — — 2 mEq/mL RT NS — F 24 hrs PI Hospira

— — 4 mEq/mL 6 hrs (USP) D5W (2004)
(continued)
Sodium RT 8.4% — 1 meq/mL RT NS84 Not specified F84 24 hrs86 PI Hospira
bicarbonate 7.5% 0.9 mEq/mL 6 hrs (USP) D5W 84
0.05-0.15 F 7 days85 (2006); 84;
SWFI84 mEq/mL85 85; 86
4.2% 0.5 mEq/mL
Sodium RT 20 mmol — 1 mmol/mL Use NS Not specified RT 24 hrs FDA-permitted PI Fresenius
glycerophosphate immediately D5W import during Kabi (2013)
(Glycophos) phosphate shortage.
Sodium RT 50 mL — 10% RT D10W Diluted with RT 24 hrs Use 0.22 micron PI Ucyclyd
phenylacetate and 6 hrs (USP) D10W ≥ 25 filter to inject into (2011)
sodium benzoate mL/kg of bag.
(Ammonul) ABW/dose
Sodium RT — — 3 mmol/mL RT NS 0.15-0.6 RT 24 hrs Stability studies PI American
phosphate 6 hrs (USP) D5W mmol/mL2 lacking (2013); 2
Sodium RT 1 gm — 100 mg/mL RT NS 15-97.6 mg/ RT 24 hrs87 For American PI American

thiosulfate 12.5 mg — 250 mg/mL 6 hrs (USP) D5W mL87 Regent (ARI) (2009); 87
product only:
5 micron filter
required during
admixture, and 0.22
micron inline filter
required during
administration
Somatropin F Provided Variable, Diluent SubQ or IM — F Diluent Do not shake. PI Lilly (2013)
(Humatrope) or SWFI based on F – 14 days 14 days Humatrope is
diluent approved for SubQ
5 mg 1.5-5 mL SWFI - F SWFI
volume used or IM use. Some
F - 6 hrs (USP) 24 hrs
brands are not
approved for IM
use, check PI.
Streptomycin RT SWFI RT NS or 100 mL88 RT 24 hrs88 Protect from light. PI Xgen
1 gm 1.8 mL 400 mg/mL 6 hrs (USP) D5W88 Approved for IM (2011); 88
use only, however IV
infusion over 30-60
min has been used.
(continued)
Sulfamethoxazole- RT 80 mg — TMP 16 mg/ RT D5W TMP Doses based on PI Teva
Trimethoprim 160 mg — mL SMX 80 48 hrs – 0.8-1 mg/mL RT 24 hrs155 Trimethoprim: (2012); 155;
(Bactrim) mg/mL MDV ≤ 200 mg à dilute 156
480 mg — ≤0.8 mg/mL RT 48 hrs156 in 250 mL
> 200 mg à dilute
to 1 mg/mL
Max concentration
= 1 mg/mL
Compatible with all
containers.
Tacrolimus RT 5 mg — 5 mg/mL Use NS 0.004-0.02 RT 24 hrs Non-PVC bag or PI Astellas
F immediately D5W mg/mL glass bottle (2011)
Talc RT NS RT NS 2.5 g/50 mL RT 12 hrs Intrapleural PI Bryan

6 hrs (USP) administration only (2012)
5 gm 50 mL 100 mg/mL Divide into (2) 60
mL syringe
Further dilute to
50 mL NS in each
syringe.
Telavancin F SWFI/ F NS 0.6-8 mg/mL RT 12 hrs EXP For doses 150-800 PI Theravance
(Vibativ) D5W/NS 6 hrs (USP) D5W F 7 d EXP mg, dilute in 100- (2014)
250 mL.
250 mg 15 mL 15 mg/mL For doses <150 mg
750 mg 45 mL 15 mg/mL or >800 mg, dilute
to conc. of 0.6-8
mg/mL.
Do not shake. Do
not tube.
Thiamine RT 200 mg — 100 mg/mL RT or F NS 100 mL89 RT 24 hrs90 Protect from light. PI APP (2002);
28 days D5W Infuse over 30 min 89; 90
(if minibag).
Thyrotropin Alfa F SWFI F Undiluted — F 24 hrs Protect from light. PI Genzyme
(Thyrogen) 1.1 mg 1.2 mL 0.9 mg/mL 6 hrs (USP) For IM (2014)
administration
(continued)
Tigecycline RT NS/D5W RT NS 100 mL F 48 hrs PI Wyeth
(Tygacil) 50 mg 5.3 mL 10 mg/mL 6 hrs D5W ≤1 mg/mL (2012)
Tobramycin RT — — 40 mg/mL RT NS 50-100 mL F 3 days PI APP (2008)

28 days – D5W RT 24 hrs
MDV
6 hrs – SDV
Tocilizumab F 80 mg — 20 mg/mL Use NS TV ≥30 kg RT or F 24 hrs Do not shake. PI Genentech
(Actemra) immediately 100 mL Protect from light. (2013)
200 mg — 20 mg/mL <30 kg 50
400 mg — 20 mg/mL mL
Tranexamic Acid RT 1 gm — 100 mg/mL NS 50-250 mL RT 24 hrs PI Mylan

D5W (2013)
Trastuzumab F Provided F NS 250 mL F 24 hrs Do not shake. PI Genentech
(Herceptin) or SWFI 28 days – Incompatible with (2010)
440 mg 20 mL 21 mg/mL BWFI D5W.
6 hrs – SWFI
Treprostinil RT 20 mg — 1 mg/mL F Undiluted — RT 72 hrs Ensure no bubbles PI United

(Remodulin) 50 mg — 2.5 mg/mL 28 days (Sub- in line. (2014)
cutaneous)
100 mg — 5 mg/mL IV infusion
200 mg — 10 mg/mL Sterile ≥0.004 mg/ RT 48 hrs
glycine mL
diluent
(Flolan)
SWFI ≥0.004 mg/ RT 4 hrs
mL F 24 hrs
NS ≥0.004 mg/ RT 4 hrs
mL F 24 hrs
(continued)
tration
Treprostinil RT 1.75 mg — 0.6 mg/mL RT Undiluted — RT 24 hrs INHALATION PI United
(Tyvaso 24 hrs ONLY (2013)
Inhalation) For Once foil pouch
nebulization containing 4 amps is
via via opened, use contents
Tyvaso within 7 days.
Inhalation
System. Usual admin rate
= 1 amp/day. Once
ampule opened
and transferred to
device, use within
24 hrs.
Protect from light.
Trichophyton F 2000 — 1000 pn F Undiluted. — F 24 hrs Pull up in TB PI Allermed
pn units unit/mL 28 days (Intradermal) syringe. (2009)
Tuberculin F 5 units — 5 units/0.1 F Undiluted. — F 24 hrs Pull up in TB PI JHP (2009)
(Aplisol) mL 28 days (Intradermal) syringe.
Valproate sodium RT 500 mg — 100 mg/mL RT NS 50 mL RT 24 hrs Infuse over ≥60 min PI Bedford
(Depacon) 6 hrs (USP) D5W Max admin rate 20 (2004); PI
mg/min Abbott (2006)
Vancomycin RT SWFI F NS 1-10 mg/mL92 F 14 days91,92,93 Defrosting frozen PI APP (2011);

500 mg 10 mL 50 mg/mL 6 hrs D5W RT 24 hrs manufactured PI Baxter
product: (2009); PI
750 mg 15 mL 50 mg/mL Defrosted at RT = Hospira
1 gm 20 mL 50 mg/mL 72 hrs (2012); 91; 92;
Defrosted in refrig = 93; 1
5 gm 100 mL 50 mg/mL RT
30 days
10 gm 95 mL 100 mg/mL 4 hrs
(continued)
tration
Vasopressin RT 20 units — 20 units/mL SDV- RT NS 0.1-1 units/ RT 24 hrs PI Par (2014)
Use D5W mL
immediately
MDV – RT
48 hrs
Vecuronium RT SWFI F NS 100 mL RT 24 hrs PI Hospira
10 mg 10 mL 1 mg/mL 6 hrs (USP) D5W 0.1-1 mg/mL 2 (2013); 2
Vedolizumab F SWFI Use NS 250 mL F 4 hrs Do not shake. Avoid PI Takeda

(Entyvio) 60 mg/mL immediately excess foaming. (2014)
300 mg 4.8 mL Reconstitute at RT.
It may take 20-30
min. Do not use
the vial if the drug
is not dissolved
within 30 minutes.
Invert vial 3 times
before withdrawing
reconstituted
solution.
Voriconazole RT SWFI Use NS 0.5-5 mg/mL F 24 hrs Infuse over 1-2 hrs. PI Roerig
(Vfend) 200 mg 19 mL 10 mg/mL immediately D5W (2011)
Warfarin RT SWFI RT Undiluted — RT 4 hrs Slow IV push over PI BMS (2010)

(Coumadin) 5.4 mg 2.7 mL 2 mg/mL 4 hrs 1-2 min.
Zidovudine RT 200 mg — 10 mg/mL RT D5W ≤ 4 mg/mL F 24 hrs PI GSK

(Retrovir) 6 hrs (USP) RT 8 hrs (2006); PI ViiV
(2010)
Zoledronic acid RT 4 mg — 0.8 mg/mL RT NS 100 mL F 24 hrs EXP Infuse over at least PI Novartis
(Zometa) 6 hrs (USP) D5W 15 minutes. (2008)
Also available
commercially as
ready-to-use premix.
Guidelines for Beyond Use Dating
References 17. Calis KA, Cullinane AM, Horne MK III. Bioactivity of

cryopreserved alteplase solutions. Am J Health Syst Pharm.
1. Trissel LA. Handbook on Injectable Drugs. 16th edition.
1999;56(20):2056-2057.
Bethesda, MD: American Society of Health System Pharma-
cists; 2011. 18. Frazin BS: Maximal dilution of Activase. Am J Hosp
Pharm. 1990;47:1016.
2. LexiComp Online Database. Wolters Kluwer Health.
Copyright 1978-2014. http://www.lexicomponline.com. 19. Semba CP, Weck S, Patapoff T. Alteplase: Stability and
Accessed May 2014. bioactivity after dilution in normal saline solution. J Vasc
3. Baxter Personal Communication. February 11, 2015. Interv Radiol. 2003;14:99-102.
Medical Affairs Information Specialist. Case number: USM15- 20. Zhang YP, Trissel LA, Stability of aminocaproic acid
04325 injection admixtures in 5% dextrose injection and 0.9%
4. Talton MA. Drug information [personal communication, sodium chloride injection. Int J Pharm Compound. 1997;1(2):
June 11, 1993]. Research Triangle Park, NC: Burroughs Well- 132-134.
come Company. 21. Trissel LA. Handbook on Injectable Drugs. 2nd ed.
5. Das Gupta V, Stewart KR. Stability of cefamandole naf- Bethesda, MD: American Society of Hospital Pharmacists;
tate and cefoxitin sodium solutions. Am J Hosp Pharm. 1981; 1980.
38:875-879. 22. Mitrano FP, Outman WR, Baptista RJ, et al. Chemical and
6. Xu QA, Zhang YP, Trissel LA, et al. Stability of Cisatracu- visual stability of amphotericin B in 5% dextrose injection
rium besylate in vials, syringes and infusion admixtures. Am J stored at 4 °C for 35 days. Am J Hosp Pharm. 1991;48:2635-
Health Syst Pharm. 1998;55:1037-1041. 2637.
7. Peddicord TE, Olsen KM, ZumBrunnen TL, et al. Sta- 23. Bakri SJ, Snyder MR, Pulido JS, et al. Six-month stabil-
bility of high concentration dopamine hydrochloride, epi- ity of bevacizumab (Avastin) binding to vascular endothelial
nephrine hydrochloride, norepinephrine bitartrate and nitro- growth factor after withdrawal into a syringe and refrigera-
glycerin in 5% dextrose injection. Am J Health Syst Pharm. tion or freezing. Retina. 2006;26(5):519-522.
1997;54:1417-1419. 24. Kiser TH, Barber GR, Robinson A. Managing the intrave-
8. Mitchell JF, Barger RC, Cantwell L. Heparin stability in nous calcium shortage: evaluation of calcium chloride stability
5% dextrose and 0.9% sodium chloride solutions. Am J Hosp in 0.9% sodium chloride and dextrose 5% water polyvinyl
Pharm. 1976;33:540-542. chloride bags. Hosp Pharm. 2012;47:27-30.
9. Yuen PC, Taddei CR, Wyka BE, et al. Compatibility and 25. Cayo L. Pharmacy Practice News. 2013;Special Edi-
stability of labetalol hydrochloride in commonly used intrave- tion:39-46. http://www.pharmacypracticenews.com/NewsAr-
nous solutions. Am J Hosp Pharm. 1983;40:1007-1009. ticles.aspx?d=Special+Edition+/+Educational+Reviews&d_
id=63. Accessed October 13, 2013.
10. Kirschenbaum HL, Lesko LJ, Medes RW, et al. Stability
of procainamide in 0.9% sodium chloride or 5% dextrose in 26. Donnelly RF. Stability of cefazolin sodium in polypro-
water. Am J Hosp Pharm. 1979;36:1464-1465. pylene syringes and polyvinylchloride minibags. Can J Hosp
11. Weber CR, Gupta VD. Stability of phenylephrine hydro- Pharm. 2011;64:241-245.
chloride in intravenous solutions. J Hosp Pharm. 1970;28: 27. Parker EA. Compatibility digest. Chloromycetin sodium
200-208. succinate injection. Am J Hosp Pharm. 1970;27:69.
12. Yücel A, Ozyalçin S, Talu GK, et al. Intravenous admin- 28. Kowaluk EA, Roberts MS, Blackburn HD, et al. Interac-
istration of caffeine sodium benzoate for postdural puncture tions between drugs and polyvinyl chloride infusion bags. Am
headache. Reg Anesth Pain Med. 1999;24(1):51-54. J Hosp Pharm. 1981;38:1308-1314.
13. Information for Healthcare Professionals Colistimethate 29. Porter WR, Johnson CA, Cohon MS, et al. Compatibility
(marketed as Coly-Mycin M and generic products). US Food and stability of clindamycin phosphate with intravenous flu-
and Drug Administration. http://www.fda.gov/CDER/DRUG/ ids. Am J Hosp Pharm. 1983;40:91-94.
InfoSheets/HCP/colistimethateHCP.htmL. Accessed June 28,
2007. 30. Gupta VD, Parasrampuria J, Bethea C, et al. Stability of
clindamycin phosphate in dextrose and saline solutions. Can J
14. Gupta V. Stability of levothyroxine sodium injection in Hosp Pharm. 1989;42:109-112.
polypropylene syringes. Int J Pharm Comp. 2000;4(6):482-483.
31. Kirkland WD, Jones RW, Ellis JR, et al. Compat-
15. Stability of acetylcysteine solution repackaged in oral ibility studies of parenteral admixtures. Am J Hosp Pharm.
syringes and associated cost savings. Am J Health Syst Pharm. 1961;18:694-699.
2007;64:762-766
32. Chin A, Liu S, Ting-Chan J, et al. Extended stability of
16. Boyd JR, Olin BR, eds. Facts and Comparisons, Drug and ascorbic acid in 5% dextrose injection and 0.9% sodium chlo-
Information. St. Louis, MO: JB Lippincott Company; 1984. ride injection. Am J Health Syst Pharm. 2005;62:1073-1074.
33. Ringwood MA. Stability of cefepime for injection for 50. Fraser GL, Riker RR. Visual compatibility of halo-
IM or IV use following constitution/dilution. Syracuse, NY: peridol lactate with injectable solutions. Am J Hosp Pharm.
Bristol-Myers Company; August 16, 1990. Data on file: 1990; 1994;51:905-906.
Tri-Pharma.
51. Rigge DC, Jones MF. Shelf lives of aseptically prepared
34. Quan AN, Quan D, Curry SC. Improving crotalidae poly- medicines--stability of hydrocortisone sodium succinate
valent immune fab reconstitution times. Am J Emerg Med. in PVC and non-PVC bags and in polypropylene syringes.
2010;28(5):593-595. J Pharm Biomed Anal. 2005;38:332.
35. Bing CM, Chamallas SN, Filibeck DJ, et al. Extended Sta- 52. Walker SE, Gray S, Schmidt B. Stability of reconstituted
bility for Parenteral Drugs. 4th ed. Bethesda, MD: American indomethacin sodium trihydrate in original vials and polypro-
Society of Health-System Pharmacists; 2009. pylene syringes. Am J Health Syst Pharm. 1998;55:154-158.
36. Lau DW, et al. PDA. J Pharm Sci Tech. 1996;50:261. 53. Greenwood BC, Chesnick MA, Szumita PM, et al. Sta-
bility of regular human insulin extemporaneously prepared
37. Preslaski CR, Mueller SW, Wempe MF, et al. Stability of in 0.9% sodium chloride in a polyvinyl chloride bag. Hosp
dexmedetomidine in polyvinyl chloride bags containing 0.9% Pharm. 2012;47:367-370.
sodium chloride. Am J Health Syst Pharm. 2013;70:1336-
1341. 54. Baxter correspondence. David Donjon, Marketing Man-
ager Sterile Fluids. Gambro Hospital; July 29, 2014.
38. Donnelly RF. Chemical stability of diphenhydramine
hydrochloride in minibags and polypropylene syringes. Can J 55. McEvoy GK, ed. AHFS Drug Information 2004. Bethesda,
Hosp Pharm. 1999;52:150. MD: American Society of Health-System Pharmacists; 2004.
39. Allwood MC. The stability of four catecholamines in 5% 56. The LifeCare Flexible I.V. Container. I.V. Additive Studies
glucose infusions. J Clin Pharm Ther. 1991;16:337-340. 97-3643. North Chicago, IL: Abbott Laboratories; 1976:111.
40. Horrow JC, Digregorio GJ, Barbieri EJ, et al. Intravenous 57. Parker EA. Compatibility digest. Isuprel hydrochloride
infusions of nitroprusside, dobutamine, and nitroglycerin are injection. Am J Hosp Pharm. 1974;31:775.
compatible. Crit Care Med. 1990;18:858-861. 58. Lecompte D, Bousselet M, Gayard D, et al. Stability study
41. Stewart JT, Warren FW, King AD. Stability of ranitidine of reconstituted and diluted solutions of calcium folinate.
hydrochloride and seven medications. Am J Hosp Pharm. Pharm Ind. 1991;53:90-94.
1994;51:1802-1807. 59. Strong DK, Decarie D, Ensom MH. Stability of levothy-
42. Allwood MC. The stability of erythromycin injection in roxine in sodium chloride for IV administration. Can J Hosp
small-volume infusions. Int J Pharm. 1990;62:R1-R3. Pharm. 2010;63(6):437-443.
43. Gupta VD, Parasrampuria J, Bethea C. Chemical stabili- 60. Gupta VD, Pramar Y. Stability of lorazepam in 5% dex-
ties of famotidine and ranitidine hydrochloride in intravenous trose injection. Int J Pharmaceut Compound. 1998;2:322-324.
admixtures. J Clin Pharm Ther: 1988;13:329-334. 61. Martens HJ, DeGoede PN, Van Loenen AC. Sorption of
44. Martens HJ. Stabilitat wasserloslicher vitamine in ver- various drugs in polyvinyl chloride, glass, and polyethylene-
schieden infusionsbenteln [Stability of water soluble vitamins lined infusion containers. Am J Hosp Pharm. 1990;47:369-373.
in different infusions]. Krankenhauspharmazie. 1989;10:359- 62. Forsyth HF. Methocarbamol (Robaxin) in orthopedic
361. conditions. JAMA. 1958;167:163-168.
45. Woods K, Steinmann W, Bruns L, et al. Stability of fos- 63. Patel PN. Methylene blue for management of ifosfamide-
carnet sodium in 0.9% sodium chloride injection. Am J Hosp induced encephalopathy. Ann Pharmacother. 2006;40(2):299-
Pharm. 1994;51:88-90. 303.
46. Fischer JH, Cwik MJ, Luer MS, et al. Stability of fosphe- 64. Pyter RA, Hsu LCC, Buddenhagen JD. Stability of meth-
nytoin sodium with intravenous solutions in glass bottles, ylprednisolone sodium succinate in 5% dextrose and 0.9%
polyvinyl chloride bags, and polypropylene syringes. Ann sodium chloride injections. Am J Hosp Pharm. 1983;40:
Pharmacother. 1997;31:553-559. 1329-1333.
47. Donnelly RF. Chemical stability of furosemide in mini- 65. Pesko LJ, Arend KA, Hagman DE, et al. Physical compat-
bags and polypropylene syringes. Int J Pharmaceut Com- ibility and stability of metoclopramide injection. Parenterals.
pound. 2002;6:468-470. 1988;5:1-3, 6-8.
48. Goodwin SD, Nix DE, Heyd A, et al. Compatibility of 66. Gupta VD. Chemical stability of metoclopramide hydro-
ciprofloxacin injection with selected drugs and solutions. Am chloride injection diluted with 0.9% sodium chloride injection
J Hosp Pharm. 1991;48(10):2166-2171. in polypropylene syringes at room temperature. Int J Pharma-
ceut Compound. 2005;9:72-74.
49. Love JN, Sachdeva DK, Bessman ES, et al. A potential role
for glucagon in the treatment of drug-induced symptomatic 67. McDonald JE, Alberti RL. (letters). Am J Hosp Pharm.
bradycardia. Chest. 1998;114(1):323-326. 1983;40:772.
68. Goodwin SD, et al. Compatibility of ciprofloxacin injec- 85. Wear J, McPherson TB, Kolling WM. Stability of sodium
tion with selected drugs and solutions. Am J Hosp Pharm. bicarbonate solutions in polyolefin bags. Am J Health Syst
1991;48:2166. Pharm. 2010;67:1026-1029.
69. Wong F, Gill MA. Stability of milrinone lactate 200 mcg/ 86. Kirkland WD, Jones RW, Ellis JR, et al. Compat-
mL in 5% dextrose injection and 0.9% sodium chloride injec- ibility studies of parenteral admixtures. Am J Hosp Pharm.
tion. Int J Pharmaceut Compound. 1998;2:168-169. 1961;18:694-699.
70. Nguyen D, Gill MA, Wong F. Stability of milrinone lactate 87. Redkar S, Dave N. Stability of sodium thiosulfate injec-
in 5% dextrose injection and 0.9% sodium chloride injection tion solutions in different diluents [technical information].
at concentrations of 400, 600, and 800 mcg/mL. Int J Pharma- Skin-Canoga Park, CA: T-Gens International Inc.; 1986.
ceut Compound. 1998;2:246-248. 88. Peloquin CQ, Berning SE. Comment: intravenous strepto-
71. Wagenknecht DM, Baaske DM, Alam AS, et al. Stability mycin [letter]. Ann Pharmacother. 1993;27:1545-1546.
of nitroglycerin solutions in polyolefin and glass containers. 89. Sechi G, Serra A. Wernicke’s encephalopathy: New clini-
Am J Hosp Pharm. 1984;41:1807-1811. cal settings and recent advances in diagnosis and management.
72. Allwood MC. The stability of four catecholamines in 5% Lancet Neurol. 2007;6(5):442-455.
glucose infusions. J Clin Pharm Ther. 1991;16:337-340. 90. Scheiner JM, Araujo MM, DeRitter E. Thiamine destruc-
tion by sodium bisulfite in infusion solutions. Am J Hosp
73. Walker SE, Law S, Garland J, et al. Stability of norepi-
Pharm. 1981;38:1911-1913.
nephrine solutions in normal saline and 5% dextrose in water.
Can J Hosp Pharm. 2010;63:113-118. 91. King JC. King Guide to Parenteral Admixtures. 1st ed.
Stockton, CA: Cutter, Inc.; 1971.
74. Tremblay M, Lessard MR, Trepanier CA, et al. Stability
of norepinephrine infusions prepared in dextrose and normal 92. Drug stability data for Intermate and Infusor portable
saline solutions. Can J Anesth. 2008;55:163-167. elastomeric infusion devices. Round Lake, IL: Baxter Health-
care Corporation; 2008.
75. Graham CL, Dukes GE, Kao CF, et al. Stability of ondan-
setron in large-volume parenteral solutions. Ann Pharmaco- 93. Walker SE, Birkhans B. Stability of intravenous
ther. 1992;26:768-771. vancomycin. Can J Hosp Pharm. 1988;41:233-242.
76. Bosso JA, Prince RA, Fox JL. Stability of ondansetron 94. Lam XM, et al. Stability and activity of alteplase with
hydrochloride in injectable solutions at -20, 5, and 25 °C. Am injectable drugs commonly used in cardiac therapy. Am
J Hosp Pharm. 1992;49:2223-2225. J Health-Syst Pharm. 1995;52:1904.
77. Casto DT. Stability of ondansetron stored in polypropyl- 95. Harper NJN, Pollard BJ, Edwards D, et al. Stability of atra-
ene syringes. Ann Pharmacother. 1994;28:712. curium in dilute solutions. Br J Anaesth. 1988;60:344P-345P.
78. Walker SE, Iazzetta J. Compatibility and stability of pen- 96. Grant HR. Compatibilities of intravenous admixtures.
Hosp Pharmacist. 1962;15:67-70.
tobarbital infusions. Anesthesiology. 1981;55:487-489.
97. Dixon FW, Weshalek J. Physical compatibility of nine
79. Hittel WP, Iafrate RP, Karnes HT, et al. Stability of pen-
drugs in various intravenous solutions. Am J Hosp Pharm.
tobarbital sodium in 5% dextrose injection and 0.9% sodium
1972; 29:822-823.
chloride injection. Am J Hosp Pharm. 1983;40:294-296.
98. Parker EA. Compatibility digest: Aminophylline intrave-
80. Gupta VD. Stability of pentobarbital sodium after recon-
nous, Staphcillin injection, Chloromycetin sodium succinate
stitution in 0.9% sodium chloride injection and repackaging injection. Am J Hosp Pharm. 1970;27:67-68.
in glass and polypropylene syringes. Int J Pharm Compound-
ing. 2001;5:482. 99. Kirkland WD, Jones RW, Ellis JR, et al. Compatibility
studies of parenteral admixtures. Am J Hosp Pharm. 1961;18:
81. Dixon FW, Weshalek J. Physical compatibility of nine 694-699.
drugs in various intravenous solutions. Am J Hosp Pharm.
1972;29:822-823. 100. Parker EA. Compatibility digest: Aramine bitartrate
injection, Diuril Lyovac. Am J Hosp Pharm. 1970;27:672-673.
82. AHFS drug information 2007. McEvoy GK, ed. Procain-
amide Hydrochloride. Bethesda, MD: American Society of 101. Janssen correspondence 00359880. Adrienne Valentino,
Health-System Pharmacists; 2007:1588-92. PharmD, Medical Information Specialist. Janssen Scientific
Affairs, LLC. September 11, 2015.
83. Sianipar A, et al. Chemical incompatibility between pro-
102. Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized
cainamide hydrochloride and glucose following intravenous
coilistin as adjunctive treatment of ventilator-associate pneu-
admixture. J Pharm Pharmacol. 1994;46:951.
monia due to multidrug-resistant Gram-negative bacteria: a
84. Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia prospective study [published online ahead of print December
[electronic version]. Denver, CO: Micromedex, Inc; 1990. 3, 2007]. Respir Med. 2008;102(3):407-412.
103. Tchiakpe L, Airaudo CB, Abdelmalik OM, et al. Stedim 120. Bing CD, et al. Hydromorphone Hydrochloride,
6 and Clearflex, two new multilayer materials for infusion Extended Stability for Parenteral Drugs. 5th ed. Bethesda MD:
containers. Comparative study of their compatibility with five American Society of Health-System Pharmacists; 2013:207.
drugs versus glass flasks and polyvinyl chloride bags. J Biomater
121. Shi A, Walker SE, Law S. Stability of ketorolac tro-
Sci Polymer Educ. 1995;7:199-206. methamine in IV solutions and waste reduction. Can J Hosp
104. Chin TH, Professional Services, Miles, Inc. [personal Pharm. 2000;53:263-269.
communication, December 3, 1993]. Data on file: 1993; Tri- 122. Newby B, et al. Stability of magnesium sulfate 20% in
Pharma. Viaflex bags. Can J Hosp Pharm. 2008;61(5):356-357.
105. Barceloux DG, Krenzelok EP, Olson K, et al. American 123. Sarver JG, Pryka R, Alexander K, et al. Stability of mag-
Academy of Clinical Toxicology practice guidelines on the nesium sulfate in 0.9% sodium chloride and lactated Ringer’s
treatment of ethylene glycol poisoning. J Toxicol Clin Toxicol. injection. Int J Pharmaceut Compound. 1998;2:385-388.
1999;37:537.
124. Thompson DF, Shimanek M. Stability and sterility study
106. Kirschenbaum HL, et al. Stability of dobutamine hydro- with magnesium sulfate admixtures. Infusion. 1983;7:83, 86.
chloride in selected large-volume parenterals. Am J Hosp
Pharm. 1982;39:1923. 125. Stability Data Review and Evaluation Request 62389,
(BREVIBLOC PREMIXED Injection Codes 2J1415 and
107. Webster AA, English BA, McGuire JM, et al. Stability of 2J1413-Out of Pouch Chemical Stability). C. Martin. August
dobutamine hydrochloride 4 mg/mL in 5% dextrose injection 27, 2012.
at 5 and 23°C. Int J Pharmaceut Compound. 1999;3:412-414.
126. Little G, Director, Drug Information, Wyeth-Ayerst
108. Allwood MC. The stability of four catecholamines in Pharmaceuticals (personal communication, March 5, 1999).
5% glucose infusions. J Clin Pharm Ther. 1991;16:337-340. Data on file: 1999; TriPharma.
109. Allwood MC. The influence of buffering on the stabil- 127. Parker WA. Methyldopa hyperpyrexia. JAMA.
ity of erythromycin injection in small-volume infusions. Int J 1974;228:1097.
Pharm. 1992;80:R7-R9.
128. Karlage K, Earhart Z, Green-Boesen K, et al. Stability
110. Donnelly RF. Chemical stability of fentanyl in polypro- of midazolam hydrochloride injection 1-mg/mL solutions
pylene syringes and polyvinyl chloride bags. Int J Pharm Com- in polyvinyl chloride and polyolefin bags. Am J Health Syst
pound. 2005;9:482. Pharm. 2011;68:1537-1540.
111. Drug stability data for Intermate and Infusor portable 129. Vecchio M, Walker SE, Iazetta J, et al. The stability of
elastomeric infusion devices. Round Lake, IL: Baxter Health- morphine intravenous infusion solutions. Can J Hosp Pharm.
care Corporation; 2008. 1988;41:5-9, 43.
112. Wright A, Hecker J. Long term stability of heparin in 130. Duafala ME, et al. Stability of morphine sulfate in infu-
dextrose-saline intravenous fluids. Int J Pharm Pract. 1995;3: sion devices and containers for intravenous administration.
253-255. Am J Hosp Pharm. 1990;47:143.
113. Joy RT, et al. Effect of pH on the stability of heparin in 131. Hagan RL, Mallett MS, Fox JL. Stability of ondansetron
5% dextrose solutions. Am J Hosp Pharm. 1979;36:618. hydrochloride and dexamethasone sodium phosphate in infu-
sion bags and syringes for 32 days. Am J Health Syst Pharm.
114. Hodby EG, Hirsh J, Adeniyi-Jones C. The influence of 1996;53:1431-1435.
drugs upon the anticoagulant activity of heparin. Can Med
Assoc J. 1972;106(5):562. 132. Guardian Laboratories. Broad Spectrum Antimicrobial
for Topical Application. Clorpactin Physician’s Reference.
115. Physical Compatibility of Parenteral Admixtures. North Revised August 2000. http://www.u-g.com.
Chicago, IL: Abbott Laboratories; 1968.
133. Boothby LA, Madabushi R, Kumar V, et al. Extended
116. Genentech correspondence. Dee Anne, Medical Liaison. stability of oxytocin in Ringer’s lactate solution at 4° and
Genentech. January 17, 2014. 25°C. Hosp Pharm. 2006;41:437-441.
117. Voges M, et al. Stability of drug additives in perito- 134. Trissel LA. Zhang Y, Douglass K, et al. Extended stabil-
neal dialysis solutions in a new container. Perit Dial Int. ity of oxytocin in common infusion solutions. Int J Pharma-
2004;24:590-595 ceut Compound. 2006;10:156-158.
118. Parker EA. Solution additive chemical incompatibility 135. Donnelly RF. Stability of pantoprazole sodium in glass
study. Am J Hosp Pharm. 1967;24:434-439. vials, polyvinyl chloride minibags, and polypropylene syringes.
119. Baxter correspondence USM15-15381. Arlene Strugeon, Can J Hosp Pharm. 2011;64:192-198.
RN, Medical Information Specialist III. Baxter Healthcare 136. Mann JM, Coleman DL, Boylan JC. Stability of par-
Corporation. June 1, 2015. enteral solutions of sodium cephalothin, cephaloridine,
potassium penicillin G (buffered) and vancomycin hydrochlo- 148. Donnelly RF. Stability of diluted ketamine packaged in
ride. Am J Hosp Pharm. 1971;28:760-763. glass vials. Can J Hosp Pharm. 2013;66:198.
137. Gupta VD, Shah KA, de la Torre M. Stability of ampicillin 149. Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous
sodium and penicillin G potassium solutions using high-pressure dihydroergotamine (DHE) for inpatient management of refrac-
liquid chromatography. Can J Pharm Sci. 1981;16:61-65. tory primary headaches. Neurology. 2011;77:1827-1832.
138. Wyatt RG, Okamato GA, Feigin RD. Stability of antibi- 150. Weeks PA, Teng Y, Wu L, et al. Chemical and physical
otics in parenteral solutions. Pediatrics. 1972;49:22-29. compatibility of an intravenous solution of epinephrine with
calcium chloride. Int J Pharmaceut Compound. 2014;18:152-
139. Phelps SJ, Cochran EB. Guidelines for Administration
158.
of Intravenous Medications to Pediatric Patients. 4th ed.
Bethesda, MD: American Society of Health-System Pharma- 151. Thur MP, Travenol Laboratories. Personal communica-
cists; 1993. tion. Data on file: 1976; TriPharma.
140. Nahata MC, Hipple TF, Strausbaugh SD. Stability of 152. Hospira personal communication. May 28, 2015. Medi-
phenobarbital solution diluted in 0.9% sodium chloride injec- cal Information Specialist. Case number: US2015-08799
tion. Am J Hosp Pharm. 1986;43:384-385.
153. Janssen personal communication. September 2, 2015.
141. Kirkland WD, Jones RW, Ellis JR, et al. Compatibility Senior Therapist Specialist. Inquire number: 00352125
studies of parenteral admixtures. Am J Hosp Pharm. 1961;18:
154. Baaske DM, DeMay JF, Latona CA, et al. Stability of
694-699.
nicardipine hydrochloride in intravenous solutions. Am J
142. Gupta VD. Chemical stability of phenylephrine hydro- Health Syst Pharm. 1996;53:1701-1705.
chloride after reconstitution in 0.9% sodium chloride injection
155. Deans KW, Lang JR, Smith DE. Stability of trime-
for infusion. Int J Pharmaceut Compound. 2004;8:153-155.
thoprim-sulfamethoxazole injection in five infusion fluids. Am
143. Genzyme correspondence MIS 1-760244661. Julia Pet- J Hosp Pharm. 1982;39:1681-1684.
ses, PharmD, Director Oncology/Hematology Medical Infor-
156. Jarosinski PF, Kennedy PE, Gallelli JF. Stability of con-
mation Services. September 11, 2015.
centrated trimethoprim-sulfamethoxazole admixtures. Am J
144. Claris Lifesciences correspondence. Despina Menon, Sr. Hosp Pharm. 1989;46:732-737.
Dir. of Compliance. Claris Lifesciences Inc.; May 21, 2014.
157. Rahman NM, Maskell NA, West A, et al. Intrapleural
145. Kirkland WD, Jones RW, Ellis JR, et al. Compatibility use of tissue plasminogen activator and DNase in pleural
studies of parenteral admixtures. Am J Hosp Pharm. 1961;18: infection [supplementary appendix appears online]. N Engl J
694-699. Med. 2011;365:518-526.
146. Reynolds JEF, ed. Martindale: The Extra Pharmaco- 158. Pharmaceutical compounding—sterile preparations
poeia. Denver, CO: Micromedex, Inc; 1991. (general information chapter <797>). In: The United States
Pharmacopeia, 36th rev, and the National Formulary, 31 ed.
147. Stucki MC, Fleury-Souverain S, Sautter AM, et al. Devel-
Rockville, MD: The United States Pharmacopeial Convention;
opment of ready-to-use ketamine hydrochloride syringes
2013:361-398. 
for safe use in post-operative pain. Eur J Hosp Pharm Sci.
2008;14:14-18.

BUD Appendix

Uploaded by

Copyright:

Available Formats

BUD Appendix

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

BUD Appendix

Uploaded by

Copyright:

Available Formats

Sentara Healthcare

Pharmacy IV Sterile Compounding Beyond Use Dating Guidelines

Vial specifics Secondary admixture specifics

Alglucosidase alfa F SWFI F NS TV 0.5-4 mg/mL F 24 hrs ** Read instructions PI Genzyme

Alpha-1 F — Provided See vial RT Provided — RT 3 hrs Do not shake. PI Talecris

≤ 0.25 mg/mL 2 days

Aztreonam RT SWFI RT or F NS NS F 7 days Defrosting frozen PI BMS

Banana bag See individual components NS — F or RT 24 hrs Protect from light. 16

Botulinum A NS F Undiluted — F 24 hrs PI Allergan

— — 2 mg/mL Diluted 2 mg/mL F 14 days152

Crotalidae F NS - RT NS 250 mL RT 4 hrs EXP Initial dose is PI Protherics

Other RT 12 hrs BUD is time from

Undiluted — F 48 hrs Flush line with NS

NS NS Not specified F 4 hrs

500 mg 10 mL 50 mg/mL D5W F 24 hrs EXP

SWFI 5 mg in 30 RT Use Intrapleural injection

1.5 mg 5 mL 0.3 mg/mL

Esmolol RT 100 mg — 10 mg/mL RT NS/D5W/ 10 mg/mL RT or F 24 hrs If foil opened – 30 d PI Baxter

Fentanyl RT 250 mcg — 50 mcg/mL RT NS (PCA) 10 mcg/mL F 14 days111 PI Hospira

Foscarnet RT 6000 mg — 24 mg/mL RT NS Peripheral F 14 days45 Compatible with PI AstraZeneca

Gentamicin RT — — 40 mg/mL F NS 50-100 mL F 48 hours48,2 PI APP (2008);

1000 mg — 125 mg/mL

Imipenem- RT SWFI RT NS 100-250 mL2 F 24 hrs Rinse vial to ensure PI Merck

Labetalol RT 200 mg — 5 mg/mL RT Undiluted — RT 30 hrs (USP) PI Prometheus

200 mcg 5 mL 40 mcg/mL mL59

500 mcg 5 mL 100 mcg/mL Undiluted — F 7 days14

Meropenem RT SWFI F NS 2.5-20 F 24 hrs PI AstraZeneca

1 gm 20 mL 50 mg/mL D5W 2.5-20 F 6 hrs

100 mg 5 mL 20 mg/mL shake vial during

Milrinone RT 50 mg — 1 mg/mL RT NS 0.2-0.4 F 14 days69,70 Premix 20 mg/100 PI Hospira

MVI F — — Vial 1: 5 mL Use NS 500-1000 mL F 24 hrs Protect from light. PI Baxter

Nicardipine RT 25 mg — 2.5 mg/mL RT NS 0.05-0.5 mg/ RT 48 hrs154 PI EKR

Palivizumab F 50 mg — 100 mg/mL Use Undiluted — Use 6 hrs Do not dilute. Do PI

Penicillin G RT SWFI F 50-100 mL Defrosting frozen PI Pfizer

Protamine RT — — 10 mg/mL RT D5W Not specified RT Use PI APP (2008)

Rasburicase F Provided F NS TV 50 mL F 24 hrs Do not bolus, shake PI Sanofi

7.5 mg 5 mL 1.5 mg/mL

Sincalide RT SWFI RT NS1 30-100 mL RT 8 hrs PI Bracco

Sodium acetate RT — — 2 mEq/mL RT NS — F 24 hrs PI Hospira

Sodium RT 1 gm — 100 mg/mL RT NS 15-97.6 mg/ RT 24 hrs87 For American PI American

Talc RT NS RT NS 2.5 g/50 mL RT 12 hrs Intrapleural PI Bryan

Tobramycin RT — — 40 mg/mL RT NS 50-100 mL F 3 days PI APP (2008)

Tranexamic Acid RT 1 gm — 100 mg/mL NS 50-250 mL RT 24 hrs PI Mylan

Treprostinil RT 20 mg — 1 mg/mL F Undiluted — RT 72 hrs Ensure no bubbles PI United

Vancomycin RT SWFI F NS 1-10 mg/mL92 F 14 days91,92,93 Defrosting frozen PI APP (2011);

Vedolizumab F SWFI Use NS 250 mL F 4 hrs Do not shake. Avoid PI Takeda

Warfarin RT SWFI RT Undiluted — RT 4 hrs Slow IV push over PI BMS (2010)

Zidovudine RT 200 mg — 10 mg/mL RT D5W ≤ 4 mg/mL F 24 hrs PI GSK

References 17. Calis KA, Cullinane AM, Horne MK III. Bioactivity of

You might also like